Gefitinib (Synonyms: 吉非替尼; ZD1839)

目录号: HY-50895 纯度: 99.94%: FAQs
Data Sheet SDS COA 产品使用指南

摩尔计算器

Gefitinib (ZD1839) 是一种有效，选择性和口服活性的 EGFR 酪氨酸激酶抑制剂，IC₅₀ 为 33 nM。Gefitinib 选择性抑制 EGF 刺激的肿瘤细胞生长 (IC₅₀ 为 54 nM)，并阻断 EGF 刺激的肿瘤细胞中 EGFR 自磷酸化。Gefitinib 还可诱导细胞自噬 (autophagy) 和凋亡 (apoptosis)，可用于癌症相关的研究，如肺癌和乳腺癌。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Gefitinib Chemical Structure

CAS No. : 184475-35-2

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥605	In-stock
100 mg	￥550	In-stock
500 mg	￥950	In-stock
1 g	￥1400	In-stock
5 g	￥2800	In-stock
10 g		询价
50 g		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Gefitinib:

MCE 顾客使用本产品发表的 133 篇科研文献

Cell Viability Assay

: Gefitinib purchased from MCE. Usage Cited in: Kaohsiung J Med Sci. 2023 Apr 14. [Abstract]; Gefitinib (0-20 μM; 24 h) significantly inhibits the viability of A549 cells.

: Gefitinib purchased from MCE. Usage Cited in: Cancer Cell. 2018 Jun 11;33(6):1061-1077.e6. [Abstract]; WT mice are either treated with vehicle or Gefitinib (100 mg/kg/day) starting one day prior to DEN injection (100 mg/kg). Livers are collected at 3 and 48 hr after DEN injection and subjected to IB analyses with the indicated antibodies.

: Gefitinib purchased from MCE. Usage Cited in: Theranostics. 2018 Jul 30;8(15):4262-4278. [Abstract]; BV2 cells are pretreated with 0.1% DMSO (Ctrl), JuA (25 µM) or JuA (25 µM) with the indicated antagonist of RTKs (Dovitinib at 1 µM, Gefitinib at 2.5 µM, SU 11248 at 2.5 µM and LDC1267 at 1 µM) for 30 min, followed by administration of Aβ42 (5 μM) for 12 h.

: Gefitinib purchased from MCE. Usage Cited in: Cell Death Dis. 2018 Feb 15;9(3):269. [Abstract]; WB is used to detect the effect of EGF treatment for 4 h on the expression of YAP with the inhibitors of EGFR or its downsream members, including Gefitinib, LY294002, Wortmannin, GSK2334470, BX-795, MK-2206, GSK1120212, and U0126 in the Si RhoA transfected HepG2 and SMMC7721 cells for 48 h in HepG2 and SMMC7721 cells.

: Gefitinib purchased from MCE. Usage Cited in: Oncogene. 2018 Aug;37(31):4300-4312. [Abstract]; Western blot analysis of E-cadherin and vimentin in HCC827 xenograft tumors treated with Gefitinib daily for 6-8 weeks until tumors regrown (resistant) or saline for 1 week (sensitive) (left panel).

: Gefitinib purchased from MCE. Usage Cited in: Oncol Rep. 2018 Oct;40(4):2242-2250. [Abstract]; Effects of Gefitinib(G) and SC 58635 (Cel) on ABCB1 (MDR1), FOXM1 and Bcl 2 protein levels in PC3/DR and DU145/DR cell lines. The effects of Gefitinib, SC 58635 and their combination on ABCB1 (MDR1), FOXM1 and Bcl 2 expression in the PC3/DR and DU145/DR cell lines are determined by a western blot assay.

: Gefitinib purchased from MCE. Usage Cited in: Breast Cancer Res. 2017 Aug 4;19(1):90. [Abstract]; The effect of Gefitinib-FTY720 treatment on CD44 expression in TNBC cell lines. HCC1806, Hs578T, and MDA-MB-468 TNBC cell lines at ~40% confluence in 12-well plates are exposed for 24 h to Gefitinib (Gef: 0.1 to 10 μM), with or without the addition of 1.5 μM FTY720.

: Gefitinib purchased from MCE. Usage Cited in: Exp Cell Res. 2017 Dec 15;361(2):246-256. [Abstract]; Western blot analysis for p21, p-p21, Cyclin D1. Bcl-2, Caspase 3, Cleaved Caspase 3, Caspase 9, Cleaved Caspase 9 and Bax in HCC827-GR and PC-9-GR cells treated with control, Efatutazone alone, Gefitinib alone, or Efatutazone combined with gefitinib for 48 h.

: Gefitinib purchased from MCE. Usage Cited in: Mol Med Rep. 2017 Sep;16(3):3475-3481. [Abstract]; Cyclin B1 and Cdk1 protein expression levels are significantly downregulated in NCI-H1975 cells treated with the combination of DHA (5 µM) and Gefitinib (10 µM).

: Gefitinib purchased from MCE. Usage Cited in: Chem Pharm Bull (Tokyo). 2017 Aug 1;65(8):768-775. [Abstract]; Changes in Bcl-2 protein expression in MCF-7 cells after treatment with 2CdA, BMS-354825 or Gefitinib alone or in combination for 12 h. Expression of Bcl-2 protein is analyzed by western blotting analysis.

Gefitinib 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 EGFR 亚型特异性产品:

查看所有亚型

EGFR/ErbB1/HER1 ErbB2/HER2 ErbB3/HER3 ErbB4/HER4

生物活性
纯度 & 产品资料
参考文献

生物活性

Gefitinib (ZD1839) is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC₅₀ of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC₅₀ of 54 nM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib also induces autophagy and cell apoptosis, which can be used for cancer related research, such as Lung cancer and breast cancer ^[1]^[2]^[5].

IC₅₀ & Target^[1]

EGFR

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
16HBE14o-	IC₅₀	1.601 μM Compound: Gefitinib	Antiproliferative activity against human 16HBE cells expressing wild type EGFR after 72 hrs by MTT assay Antiproliferative activity against human 16HBE cells expressing wild type EGFR after 72 hrs by MTT assay	[PMID: 23792318]
16HBE14o-	IC₅₀	12.71 μM Compound: Iressa	Antiproliferative activity against human 16HBE cells after 72 hrs by MTT assay Antiproliferative activity against human 16HBE cells after 72 hrs by MTT assay	[PMID: 24607591]
16HBE14o-	IC₅₀	12.71 μM Compound: gefitinib	Cytotoxicity against human 16HBE14o- cells harboring wild type EGFR assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human 16HBE14o- cells harboring wild type EGFR assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23668441]
A-375	IC₅₀	20.55 μM Compound: Gefitinib	Antiproliferative activity against human A375 cells after 48 hrs by MTT assay Antiproliferative activity against human A375 cells after 48 hrs by MTT assay	[PMID: 20304537]
A-431	IC₅₀	0.023 μM Compound: 29	In vitro inhibitory activity against Epidermal growth factor receptor (EGFR-TK) from A431 vulval squamous carcinoma cells using TKI assay In vitro inhibitory activity against Epidermal growth factor receptor (EGFR-TK) from A431 vulval squamous carcinoma cells using TKI assay	[PMID: 11459659]
A-431	GI₅₀	0.514 μM Compound: Ire	Growth inhibition of human A431 cells after 72 hrs by MTT assay Growth inhibition of human A431 cells after 72 hrs by MTT assay	[PMID: 19969465]
A-431	IC₅₀	0.55 μM Compound: Gefitinib	Antiproliferative activity against human A431 cells overexpressing EGFR assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human A431 cells overexpressing EGFR assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 32139324]
A-431	IC₅₀	0.55 μM Compound: Iressa	Cytotoxicity against human A431 cells overexpressing EGFR assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A431 cells overexpressing EGFR assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 27524310]
A-431	IC₅₀	0.55 μM Compound: Gefitinib, Iressa	Cytotoxicity against human A431 cells expressing EGFR after 72 hrs by MTT assay Cytotoxicity against human A431 cells expressing EGFR after 72 hrs by MTT assay	[PMID: 24411123]
A-431	IC₅₀	1.08 μM Compound: Gifitinib	Inhibition of EGFR derived from human A431 cell membrane assessed as inhibition of poly-Glu-Tyr phosphorylation after 30 mins by ELISA assay Inhibition of EGFR derived from human A431 cell membrane assessed as inhibition of poly-Glu-Tyr phosphorylation after 30 mins by ELISA assay	[PMID: 22698782]
A-431	IC₅₀	1.1 μM Compound: Gefitinib	Inhibition of EGFR in shed membrane vesicles of human A431 cells using poly-Glu-Tyr as substrate after 30 mins by ELISA Inhibition of EGFR in shed membrane vesicles of human A431 cells using poly-Glu-Tyr as substrate after 30 mins by ELISA	[PMID: 24094432]
A-431	IC₅₀	1.282 μM Compound: Gefitinib	Antiproliferative activity against human A431 cells harboring wild-type EGFR after 72 hrs by MTT assay Antiproliferative activity against human A431 cells harboring wild-type EGFR after 72 hrs by MTT assay	[PMID: 30471829]
A-431	IC₅₀	1.33 μM Compound: Gefitinib	Antiproliferative activity against human A431 cells harboring wild type EGFR assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human A431 cells harboring wild type EGFR assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26829280]
A-431	IC₅₀	1.41 μM Compound: Gifitinib	Antiproliferative activity against human A431 cells after 48 hrs by MTT assay Antiproliferative activity against human A431 cells after 48 hrs by MTT assay	[PMID: 22698782]
A-431	EC₅₀	1.71 μM Compound: Gefitinib	Antiproliferative activity against human A431 cells expressing wild type EGFR incubated for 96 hrs measured on day 5 by CellTiterGlo assay Antiproliferative activity against human A431 cells expressing wild type EGFR incubated for 96 hrs measured on day 5 by CellTiterGlo assay	[PMID: 28853575]
A-431	IC₅₀	1.89 μM Compound: Gefitinib	Cytotoxicity against human A431 cells after 48 hrs by MTT assay Cytotoxicity against human A431 cells after 48 hrs by MTT assay	10.1007/s00044-013-0734-x
A-431	IC₅₀	1.98 μM Compound: Gefitinib	Antiproliferative activity against human A431 cells after 72 hrs by MTT assay Antiproliferative activity against human A431 cells after 72 hrs by MTT assay	[PMID: 24094432]
A-431	IC₅₀	12.05 μM Compound: 1	Cytotoxicity against EGFR overexpressing human A431 cells after 24 hrs by MTT assay Cytotoxicity against EGFR overexpressing human A431 cells after 24 hrs by MTT assay	[PMID: 18771819]
A-431	IC₅₀	12.58 μM Compound: Gefitinib	Antiproliferative activity against EGFR over-expressing human A431 cells after 48 hrs by MTT assay Antiproliferative activity against EGFR over-expressing human A431 cells after 48 hrs by MTT assay	[PMID: 28236592]
A-431	IC₅₀	16.02 μM Compound: Gefitinib	Antiproliferative activity against human A-431 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human A-431 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 34147910]
A-431	IC₅₀	2.15 μM Compound: Gfb	Antiproliferative activity against human A431 cells overexpressing EGFR after 72 hrs by MTS assay Antiproliferative activity against human A431 cells overexpressing EGFR after 72 hrs by MTS assay	[PMID: 22339342]
A-431	EC₅₀	2.2 μM Compound: Gefitinib	Antiproliferative activity against human A431 cells harboring wild type EGFR assessed as growth inhibition after 96 hrs by CellTiter-Glo assay Antiproliferative activity against human A431 cells harboring wild type EGFR assessed as growth inhibition after 96 hrs by CellTiter-Glo assay	[PMID: 28603991]
A-431	IC₅₀	2.47 μM Compound: Gefitinib	Antiproliferative activity against human A431 cells after 72 hrs by MTT assay Antiproliferative activity against human A431 cells after 72 hrs by MTT assay	[PMID: 30508379]
A-431	IC₅₀	2.6 μM Compound: 1	Antiproliferative activity against human A-431 cells harboring wild type EGFR assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human A-431 cells harboring wild type EGFR assessed as inhibition of cell growth by MTT assay	[PMID: 31869655]
A-431	IC₅₀	2.98 μM Compound: Gefitinib	Antiproliferative activity against human A-431 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human A-431 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 32739648]
A-431	IC₅₀	24.55 μM Compound: Gefitinib	Antiproliferative activity against human A-431 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Antiproliferative activity against human A-431 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 34147910]
A-431	IC₅₀	3.3 μM Compound: 1; Iressa	Antiproliferative activity against human A431 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human A431 cells incubated for 72 hrs by MTT assay	[PMID: 28395219]
A-431	IC₅₀	3.308 μM Compound: 1	Antiproliferative activity against wild type human A431 cells after 48 hrs by MTT assay Antiproliferative activity against wild type human A431 cells after 48 hrs by MTT assay	[PMID: 27634676]
A-431	IC₅₀	3.308 μM Compound: Gefitinib	Antiproliferative activity against human A-431 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human A-431 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 32739648]
A-431	IC₅₀	3.74 μM Compound: Gefitinib	Antiproliferative activity against human A431 cells after 72 hrs by MTT assay Antiproliferative activity against human A431 cells after 72 hrs by MTT assay	[PMID: 26706113]
A-431	IC₅₀	31.2 μM Compound: IRESSA; ZD1839	Cytotoxicity against human A431 cells measured after 24 hrs by WST-1 assay Cytotoxicity against human A431 cells measured after 24 hrs by WST-1 assay	[PMID: 33260051]
A-431	IC₅₀	32.17 μM Compound: Gefitinib	Antiproliferative activity against human A-431 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay Antiproliferative activity against human A-431 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	[PMID: 34147910]
A-431	IC₅₀	33 nM Compound: 1	Inhibition of EGFR in human A431 cell membranes preincubated for 30 mins prior to addition of peptide substrate and [gamma32]-ATP measured after 10 mins by scintillation counting method Inhibition of EGFR in human A431 cell membranes preincubated for 30 mins prior to addition of peptide substrate and [gamma32]-ATP measured after 10 mins by scintillation counting method	[PMID: 27769671]
A-431	IC₅₀	4 μM Compound: Gefitinib	Antiproliferative activity against human A431 cells after 48 hrs by Celltiter-Glo assay Antiproliferative activity against human A431 cells after 48 hrs by Celltiter-Glo assay	[PMID: 25409491]
A-431	IC₅₀	4 μM Compound: Gefitinib	Inhibition of wild type EGFR in human A431 cells assessed as growth inhibition after 48 hrs by MTT assay Inhibition of wild type EGFR in human A431 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 24900594]
A-431	IC₅₀	4 μM Compound: Gefitinib	Cytotoxicity against human A431 cells incubated for 72 hrs by MTT assay Cytotoxicity against human A431 cells incubated for 72 hrs by MTT assay	[PMID: 23116168]
A-431	IC₅₀	4.45 μM Compound: ZD1839	Antiproliferative activity against human A431 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human A431 cells incubated for 72 hrs by MTT assay	[PMID: 31202990]
A-431	IC₅₀	4.45 μM Compound: Gefitinib	Antiproliferative activity against human A431 cells harboring wild type EGFR after 72 hrs by MTT assay Antiproliferative activity against human A431 cells harboring wild type EGFR after 72 hrs by MTT assay	[PMID: 29421573]
A-431	IC₅₀	4.45 μM Compound: Gefitinib	Antiproliferative activity against human A431 cells harboring wild type EGFR after 72 hrs by MTT assay Antiproliferative activity against human A431 cells harboring wild type EGFR after 72 hrs by MTT assay	[PMID: 28711703]
A-431	IC₅₀	4.485 μM Compound: Iressa	Antiproliferative activity against human A431 cells overexpressing WT EGFR after 72 hrs by MTT assay Antiproliferative activity against human A431 cells overexpressing WT EGFR after 72 hrs by MTT assay	[PMID: 24607591]
A-431	IC₅₀	4.485 μM Compound: gefitinib	Cytotoxicity against human A431 cells overexpressing wild type EGFR assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A431 cells overexpressing wild type EGFR assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23668441]
A-431	IC₅₀	4.58 μM Compound: Gefitinib	Antiproliferative activity against human A431 cells overexpressing wild-type EGFR after 72 hrs by MTT assay Antiproliferative activity against human A431 cells overexpressing wild-type EGFR after 72 hrs by MTT assay	[PMID: 27387355]
A-431	IC₅₀	6.12 μM Compound: Gefitinib	Antiproliferative activity against human A431 cells harboring wild type EGFR assessed as decrease in cell viability after 72 hrs by MTT assay Antiproliferative activity against human A431 cells harboring wild type EGFR assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 28385595]
A-431	IC₅₀	768 nM Compound: Gefitinib	Antiproliferative activity against human A431 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer glo luminescent cell viability assay Antiproliferative activity against human A431 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer glo luminescent cell viability assay	[PMID: 29523467]
A-431	IC₅₀	8.37 μM Compound: Gefitinib	Antiproliferative activity against human A-431 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human A-431 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33640672]
A-431	IC₅₀	8.982 μM Compound: Gefitinib	Antiproliferative activity against human A431 cells expressing wild type EGFR after 72 hrs by MTT assay Antiproliferative activity against human A431 cells expressing wild type EGFR after 72 hrs by MTT assay	[PMID: 23792318]
A498	GI₅₀	0.4 μM Compound: Gefitinib	Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
A498	IC₅₀	8.6 μM Compound: 1, Iressa	Antiproliferative activity against human A498 cells expressing EGFR and SRC by MTT assay Antiproliferative activity against human A498 cells expressing EGFR and SRC by MTT assay	[PMID: 22818848]
A549	IC₅₀	> 10 μM Compound: Gefitinib	Cytotoxicity against human A549 cells after 48 hrs by CellTiter-Glo assay Cytotoxicity against human A549 cells after 48 hrs by CellTiter-Glo assay	[PMID: 24900594]
A549	IC₅₀	> 10 μM Compound: 1	Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay	[PMID: 31787359]
A549	IC₅₀	> 10 μM Compound: Gefitinib	Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 27387355]
A549	IC₅₀	> 10000 nM Compound: Gefitinib	Antiproliferative activity against human A549 cells harboring wild-type EGFR after 72 hrs by EZ-Cytox assay Antiproliferative activity against human A549 cells harboring wild-type EGFR after 72 hrs by EZ-Cytox assay	[PMID: 30554954]
A549	IC₅₀	> 50 μM Compound: Gefitinib	Growth inhibition of human A549 cells expressing EGFR incubated for 72 hrs by CCK8 assay Growth inhibition of human A549 cells expressing EGFR incubated for 72 hrs by CCK8 assay	[PMID: 35880853]
A549	IC₅₀	0.007 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells harboring wild type EGFR assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human A549 cells harboring wild type EGFR assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32402937]
A549	IC₅₀	0.13 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells assessed as cell growth by MTT assay Antiproliferative activity against human A549 cells assessed as cell growth by MTT assay	[PMID: 26003342]
A549	IC₅₀	10.07 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 30471829]
A549	IC₅₀	10.07 μM Compound: 1; Iressa	Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay	[PMID: 28395219]
A549	IC₅₀	10.08 μM Compound: Gefitinib, Iressa	Antiproliferative activity against human A549 cells overexpressing EGFR gene after 48 hrs by MTT assay Antiproliferative activity against human A549 cells overexpressing EGFR gene after 48 hrs by MTT assay	[PMID: 22119130]
A549	IC₅₀	10.21 μM Compound: Gfb	Antiproliferative activity against human A549 cells expressing wild type EGFR coexpressing k-Ras mutant after 72 hrs by MTS assay Antiproliferative activity against human A549 cells expressing wild type EGFR coexpressing k-Ras mutant after 72 hrs by MTS assay	[PMID: 22339342]
A549	IC₅₀	10.45 μM Compound: Gefitinib	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29496411]
A549	IC₅₀	11.02 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human A549 cells after 48 hrs by CCK-8 assay	[PMID: 26343825]
A549	IC₅₀	11.08 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 30508379]
A549	IC₅₀	11.67 μM Compound: 3	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation under hypoxia conditions after 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation under hypoxia conditions after 72 hrs by SRB assay	[PMID: 25468044]
A549	IC₅₀	11.8 μM Compound: Gifitinib	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 22698782]
A549	IC₅₀	12.08 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 28711702]
A549	IC₅₀	12.17 μM Compound: 3	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation under normoxia conditions after 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation under normoxia conditions after 72 hrs by SRB assay	[PMID: 25468044]
A549	IC₅₀	12.92 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 24094432]
A549	IC₅₀	1260 nM Compound: Gefitinib	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 29576272]
A549	IC₅₀	13.26 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells highly expressing EGFR after 48 hrs by MTT assay Antiproliferative activity against human A549 cells highly expressing EGFR after 48 hrs by MTT assay	[PMID: 35247755]
A549	IC₅₀	13.32 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by cck8 assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by cck8 assay	[PMID: 27234887]
A549	IC₅₀	13.59 μM Compound: ZD-1839, IRESSA	Cytotoxicity against human A549 cells after 96 hrs by MTT assay Cytotoxicity against human A549 cells after 96 hrs by MTT assay	[PMID: 18313807]
A549	IC₅₀	14.803 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay	[PMID: 31488358]
A549	IC₅₀	15.58 μM Compound: Iressa	Antiproliferative activity against k-RAS dependent human A549 cells overexpressing WT EGFR after 72 hrs by MTT assay Antiproliferative activity against k-RAS dependent human A549 cells overexpressing WT EGFR after 72 hrs by MTT assay	[PMID: 24607591]
A549	IC₅₀	15.58 μM Compound: gefitinib	Cytotoxicity against human A549 cells harboring wild type EGFR and k-RAS mutation assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human A549 cells harboring wild type EGFR and k-RAS mutation assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23668441]
A549	IC₅₀	15.59 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33640672]
A549	IC₅₀	15.79 μM Compound: Gefitinib	Growth inhibition of human A549 cells incubated for 5 days by SRB assay Growth inhibition of human A549 cells incubated for 5 days by SRB assay	[PMID: 32145644]
A549	IC₅₀	17.9 μM Compound: Iressa(TM)	Antiproliferative activity against human A549 after 18 hrs by MTT assay Antiproliferative activity against human A549 after 18 hrs by MTT assay	[PMID: 30826188]
A549	EC₅₀	18.7 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells harboring KRAS-G12S mutant incubated for 96 hrs measured on day 5 by CellTiterGlo assay Antiproliferative activity against human A549 cells harboring KRAS-G12S mutant incubated for 96 hrs measured on day 5 by CellTiterGlo assay	[PMID: 28853575]
A549	IC₅₀	2.11 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 24 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 24 hrs by MTT assay	[PMID: 31431361]
A549	IC₅₀	2.17 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 32739648]
A549	IC₅₀	2.64 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells by CCK8 assay Antiproliferative activity against human A549 cells by CCK8 assay	[PMID: 34922028]
A549	IC₅₀	2.65 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 32739648]
A549	IC₅₀	2.69 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells expressing wild type EGFR assessed as inhibition in cell viability after 72 hrs by CCK8 assay Antiproliferative activity against human A549 cells expressing wild type EGFR assessed as inhibition in cell viability after 72 hrs by CCK8 assay	[PMID: 34794818]
A549	IC₅₀	2.86 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay	[PMID: 26346367]
A549	GI₅₀	2.86 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells after 48 hrs in presence of 10% FBS by MTT method Antiproliferative activity against human A549 cells after 48 hrs in presence of 10% FBS by MTT method	[PMID: 27515719]
A549	IC₅₀	2.96 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 30503938]
A549	IC₅₀	20 μM Compound: Gefitinib	Antiproliferative activity against wild type human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against wild type human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31446247]
A549	IC₅₀	20.3 μM Compound: 1	Cytotoxicity against human A549 cells after 72 hrs by CCK-8 assay Cytotoxicity against human A549 cells after 72 hrs by CCK-8 assay	[PMID: 23973168]
A549	IC₅₀	21.17 μM Compound: ZD1839	Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay	[PMID: 31202990]
A549	IC₅₀	21.17 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells harboring wild type EGFR/K-ras mutant after 72 hrs by MTT assay Antiproliferative activity against human A549 cells harboring wild type EGFR/K-ras mutant after 72 hrs by MTT assay	[PMID: 29421573]
A549	IC₅₀	21.17 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells harboring wild type EGFR/K-Ras mutant after 72 hrs by MTT assay Antiproliferative activity against human A549 cells harboring wild type EGFR/K-Ras mutant after 72 hrs by MTT assay	[PMID: 28711703]
A549	IC₅₀	21.9 μM Compound: Gefitinib	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 28927795]
A549	IC₅₀	22.5 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 28462838]
A549	IC₅₀	24.25 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 27132165]
A549	IC₅₀	29.43 μM Compound: 1	Antiproliferative activity against human A549 cells harboring K-ras mutation after 48 hrs by MTT assay Antiproliferative activity against human A549 cells harboring K-ras mutation after 48 hrs by MTT assay	[PMID: 27634676]
A549	IC₅₀	3.53 μM Compound: Gefitinib	Cytotoxicity against human A549 cells incubated for 2 to 4 hrs by MTT assay Cytotoxicity against human A549 cells incubated for 2 to 4 hrs by MTT assay	[PMID: 33771586]
A549	IC₅₀	36.21 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells harboring EGFR K-ras mutant assessed as decrease in cell viability after 72 hrs by MTT assay Antiproliferative activity against human A549 cells harboring EGFR K-ras mutant assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 28385595]
A549	IC₅₀	37.93 μM Compound: Gefitinib	Cytotoxicity against human A549 cells after 4 to 5 days by MTT assay Cytotoxicity against human A549 cells after 4 to 5 days by MTT assay	[PMID: 20466555]
A549	IC₅₀	39.7 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells harboring K-ras mutation assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human A549 cells harboring K-ras mutation assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26829280]
A549	IC₅₀	39.9 nM Compound: 1, Iressa	Inhibition of wild type EGFR autophosphorylation in human A549 cells incubated for 1 hr followed by compound washout measured at 1 hr by Western blot analysis Inhibition of wild type EGFR autophosphorylation in human A549 cells incubated for 1 hr followed by compound washout measured at 1 hr by Western blot analysis	[PMID: 23988354]
A549	IC₅₀	4.626 μM Compound: Gefitinib	Antiproliferative activity against wild type EGFR/k-Ras dependent human A549 cells after 72 hrs by MTT assay Antiproliferative activity against wild type EGFR/k-Ras dependent human A549 cells after 72 hrs by MTT assay	[PMID: 23792318]
A549	IC₅₀	498 nM Compound: 1, Iressa	Inhibition of wild type EGFR autophosphorylation in human A549 cells incubated for 1 hr followed by compound washout measured after 8 hrs by Western blot analysis Inhibition of wild type EGFR autophosphorylation in human A549 cells incubated for 1 hr followed by compound washout measured after 8 hrs by Western blot analysis	[PMID: 23988354]
A549	IC₅₀	5 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells harboring wild type EGFR after 48 hrs by MTT assay Antiproliferative activity against human A549 cells harboring wild type EGFR after 48 hrs by MTT assay	[PMID: 28236592]
A549	IC₅₀	5.74 μM Compound: 1	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 30655941]
A549	IC₅₀	5.76 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 26706113]
A549	IC₅₀	60 nM Compound: 1	Inhibition of wild type EGFR autophosphorylation in human A549 cells by Western blot analysis Inhibition of wild type EGFR autophosphorylation in human A549 cells by Western blot analysis	[PMID: 30472599]
A549	IC₅₀	7 μM Compound: gefitinib	Antiproliferative activity against human A549 cells after 72 hrs by trypan blue exclusion method Antiproliferative activity against human A549 cells after 72 hrs by trypan blue exclusion method	[PMID: 19268405]
A549	GI₅₀	7.94 μM Compound: Gefitinib	Growth inhibition of human A549 cells incubated for 48 hrs by SRB assay Growth inhibition of human A549 cells incubated for 48 hrs by SRB assay	[PMID: 31023512]
A549	GI₅₀	7.94 μM Compound: Gefitinib	Growth inhibition of human A549/ATCC cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human A549/ATCC cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
A549	IC₅₀	8.27 μM Compound: Gefitinib	Cytotoxicity against human A549 cells after 72 hrs by SRB assay Cytotoxicity against human A549 cells after 72 hrs by SRB assay	[PMID: 29407971]
A549	IC₅₀	8.28 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells by MTT assay Antiproliferative activity against human A549 cells by MTT assay	[PMID: 26560049]
A549	IC₅₀	8.4 μM Compound: gefitinib	Cytotoxicity against human A549 cells assessed as inhibition of cell viability after 72 hrs by CellTiter-Glo assay Cytotoxicity against human A549 cells assessed as inhibition of cell viability after 72 hrs by CellTiter-Glo assay	[PMID: 26192023]
A549	IC₅₀	8.51 μM Compound: Gefitinib	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	10.1007/s00044-013-0734-x
A549	IC₅₀	9.28 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells assessed as viable cells after 48 hrs by CCK8 assay Antiproliferative activity against human A549 cells assessed as viable cells after 48 hrs by CCK8 assay	[PMID: 26879314]
A549	GI₅₀	9.3 μM Compound: Gefitinib	Growth inhibition of human A549 cells after 48 hrs by MTT assay Growth inhibition of human A549 cells after 48 hrs by MTT assay	[PMID: 28291344]
A549	IC₅₀	9.86 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells harboring wild type EGFR/k-Ras mutation after 72 hrs by MTT assay Antiproliferative activity against human A549 cells harboring wild type EGFR/k-Ras mutation after 72 hrs by MTT assay	[PMID: 26451770]
A549	IC₅₀	9.86 μM Compound: Gefitinib	Antiproliferative activity against human A549 cells harboring wild type EGFR after 48 hrs by SRB assay Antiproliferative activity against human A549 cells harboring wild type EGFR after 48 hrs by SRB assay	[PMID: 28366268]
ASPC1	IC₅₀	6.73 μM Compound: Gefitinib	Antiproliferative activity against human Aspc-1 cells after 72 hrs by MTT assay Antiproliferative activity against human Aspc-1 cells after 72 hrs by MTT assay	[PMID: 30471829]
B16-F10	ED₅₀	0.91 μg/mL Compound: Gefitinib	Cytotoxicity against Homo sapiens (human) B16F10 cells after 72 hr by MTT assay Cytotoxicity against Homo sapiens (human) B16F10 cells after 72 hr by MTT assay	10.1007/s00044-012-0309-2
B16-F10	IC₅₀	2.2 μM Compound: Gefitinib	Antiproliferative activity against mouse B16F10 cells after 24 hrs by MTT assay Antiproliferative activity against mouse B16F10 cells after 24 hrs by MTT assay	[PMID: 25866240]
BaF3	IC₅₀	10.6 nM Compound: Gefitinib	Antiproliferative activity against mouse BaF3 cells expressing Del19 assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay Antiproliferative activity against mouse BaF3 cells expressing Del19 assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay	[PMID: 36384036]
BaF3	IC₅₀	12.5 nM Compound: Gefitinib	Antiproliferative activity against mouse BaF3 cells expressing De119/C797S assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay Antiproliferative activity against mouse BaF3 cells expressing De119/C797S assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay	[PMID: 36384036]
BaF3	IC₅₀	1757 nM Compound: Gefitinib	Antiproliferative activity against mouse BaF3 cells expressing Ex20 insertion GV mutant assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay Antiproliferative activity against mouse BaF3 cells expressing Ex20 insertion GV mutant assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay	[PMID: 36384036]
BaF3	IC₅₀	21.8 nM Compound: Gefitinib	Antiproliferative activity against mouse BaF3 cells expressing L858R assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay Antiproliferative activity against mouse BaF3 cells expressing L858R assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay	[PMID: 36384036]
BaF3	IC₅₀	2779.2 nM Compound: Gefitinib	Antiproliferative activity against mouse BaF3 cells expressing Ex20 insertion NPG mutant assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay Antiproliferative activity against mouse BaF3 cells expressing Ex20 insertion NPG mutant assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay	[PMID: 36384036]
BaF3	IC₅₀	53.6 nM Compound: Gefitinib	Antiproliferative activity against mouse BaF3 cells expressing EGFR WT assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay Antiproliferative activity against mouse BaF3 cells expressing EGFR WT assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay	[PMID: 36384036]
BaF3	IC₅₀	54.2 nM Compound: Gefitinib	Antiproliferative activity against mouse BaF3 cells expressing L858R/C797S assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay Antiproliferative activity against mouse BaF3 cells expressing L858R/C797S assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay	[PMID: 36384036]
BaF3	IC₅₀	6981.5 nM Compound: Gefitinib	Antiproliferative activity against mouse BaF3 cells expressing Ex20 insertion SVD mutant assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay Antiproliferative activity against mouse BaF3 cells expressing Ex20 insertion SVD mutant assessed as cell viability measured after 72 hrs hrs by CellTiter Glo assay	[PMID: 36384036]
BEAS-2B	IC₅₀	13.94 μM Compound: Iressa	Antiproliferative activity against human BEAS2B cells after 72 hrs by MTT assay Antiproliferative activity against human BEAS2B cells after 72 hrs by MTT assay	[PMID: 24607591]
BEAS-2B	IC₅₀	13.94 μM Compound: gefitinib	Cytotoxicity against human BEAS2B cells harboring wild type EGFR assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human BEAS2B cells harboring wild type EGFR assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23668441]
Bel-7402	IC₅₀	11.21 μM Compound: Gef	Antiproliferative activity against human Bel-7402 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human Bel-7402 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 32827851]
BT-474	IC₅₀	0.36 μM Compound: Iressa	Cytotoxicity against human BT474 cells overexpressing HER2 assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human BT474 cells overexpressing HER2 assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 27524310]
BT-474	IC₅₀	0.36 μM Compound: Gefitinib, Iressa	Cytotoxicity against human BT474 cells expressing HER2 after 72 hrs by MTT assay Cytotoxicity against human BT474 cells expressing HER2 after 72 hrs by MTT assay	[PMID: 24411123]
BT-474	IC₅₀	0.365 μM Compound: Gefitinib	Antiproliferative activity against human BT474 cells overexpressing HER2 assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human BT474 cells overexpressing HER2 assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 32139324]
BT-474	IC₅₀	0.53 μM Compound: Gefitinib	Antiproliferative activity against human BT474 cells after 72 hrs by MTT assay Antiproliferative activity against human BT474 cells after 72 hrs by MTT assay	[PMID: 27132165]
BT-474	IC₅₀	1.24 μM Compound: Gefitinib	Cytotoxicity against human BT474 cells expressing Her2 assessed as reduction in cell viability after 72 hrs by cell titer-glo luminescence assay Cytotoxicity against human BT474 cells expressing Her2 assessed as reduction in cell viability after 72 hrs by cell titer-glo luminescence assay	[PMID: 27288180]
BT-474	EC₅₀	300 nM Compound: Iressa	Antiproliferative activity against human BT474 cells overexpressing ERBb2 after 3 days by methylene blue staining Antiproliferative activity against human BT474 cells overexpressing ERBb2 after 3 days by methylene blue staining	[PMID: 19028424]
BT-549	IC₅₀	6.56 μM Compound: Gefitinib	Cytotoxicity against human BT549 cells after 72 hrs by SRB assay Cytotoxicity against human BT549 cells after 72 hrs by SRB assay	[PMID: 29407971]
Calu-3	IC₅₀	0.985 μM Compound: Gefitinib	Antiproliferative activity against human Calu3 cells overexpressing HER2 assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human Calu3 cells overexpressing HER2 assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 32139324]
Calu-3	IC₅₀	0.99 μM Compound: Gefitinib, Iressa	Cytotoxicity against human Calu3 cells expressing HER2 after 72 hrs by MTT assay Cytotoxicity against human Calu3 cells expressing HER2 after 72 hrs by MTT assay	[PMID: 24411123]
Calu-3	IC₅₀	1.6 μM Compound: Gefitinib	Cytotoxicity against human Calu3 cells incubated for 72 hrs by MTT assay Cytotoxicity against human Calu3 cells incubated for 72 hrs by MTT assay	[PMID: 23116168]
Calu-3	IC₅₀	4.52 μM Compound: Gefitinib	Antiproliferative activity against human Calu-3 cells by CCK8 assay Antiproliferative activity against human Calu-3 cells by CCK8 assay	[PMID: 34922028]
CCRF-CEM	GI₅₀	5.01 μM Compound: Gefitinib	Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by SRB assay Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by SRB assay	[PMID: 31023512]
CCRF-CEM	GI₅₀	5.01 μM Compound: Gefitinib	Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human CCRF-CEM cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
CHO-K1	GI₅₀	43.7 μM Compound: Gefitinib	Growth inhibition of CHOK1 cells after 48 hrs by MTT assay Growth inhibition of CHOK1 cells after 48 hrs by MTT assay	[PMID: 28291344]
CL97	IC₅₀	10 μM Compound: Gefitinib	Antiproliferative activity against human CL97 cells harbouring EGFR G719A/T790M mutant assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human CL97 cells harbouring EGFR G719A/T790M mutant assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31446247]
CNE	IC₅₀	23.5 μM Compound: Gefitinib	Antiproliferative activity against human CNE cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human CNE cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 32739648]
CWR22R	IC₅₀	14 μM Compound: Gefitinib	Growth inhibition of human 22Rv1 cells after 5 days by SRB assay Growth inhibition of human 22Rv1 cells after 5 days by SRB assay	[PMID: 32484346]
DU-145	IC₅₀	> 100 μM Compound: Gefitinib	Antiproliferative activity against human DU145 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human DU145 cells incubated for 72 hrs by MTT assay	[PMID: 31488358]
DU-145	IC₅₀	> 100 μM Compound: 2	Cytotoxicity against human DU145 cells after 72 hrs by MTT assay Cytotoxicity against human DU145 cells after 72 hrs by MTT assay	[PMID: 23871909]
DU-145	IC₅₀	42.17 μM Compound: Gefitinib	Cytotoxicity against human DU145 cells after 4 to 5 days by MTT assay Cytotoxicity against human DU145 cells after 4 to 5 days by MTT assay	[PMID: 20466555]
DU-145	IC₅₀	7.3 μM Compound: Gefitinib	Growth inhibition of human DU145 cells after 5 days by SRB assay Growth inhibition of human DU145 cells after 5 days by SRB assay	[PMID: 32484346]
DU-145	IC₅₀	8.63 μM Compound: Gefitinib	Antiproliferative activity against human DU145 cells after 72 hrs by MTT assay Antiproliferative activity against human DU145 cells after 72 hrs by MTT assay	[PMID: 28711702]
ECa-109 cell line	IC₅₀	26.47 μM Compound: Gefitinib	Cytotoxicity against human ECa-109 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human ECa-109 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32866757]
FaDu	IC₅₀	0.05 μM Compound: Gefitinib	Cytotoxicity against human FADU cells incubated for 72 hrs by MTT assay Cytotoxicity against human FADU cells incubated for 72 hrs by MTT assay	[PMID: 23116168]
HCC827	EC₅₀	< 0.014 μM Compound: Gefitinib	Antiproliferative activity against human HCC827 cells harboring EGFR-delE746_A750 mutant incubated for 96 hrs measured on day 5 by CellTiterGlo assay Antiproliferative activity against human HCC827 cells harboring EGFR-delE746_A750 mutant incubated for 96 hrs measured on day 5 by CellTiterGlo assay	[PMID: 28853575]
HCC827	IC₅₀	0.0015 μM Compound: Gefitinib	Cytotoxicity against human HCC827 cells incubated for 72 hrs by MTT assay Cytotoxicity against human HCC827 cells incubated for 72 hrs by MTT assay	[PMID: 23116168]
HCC827	IC₅₀	0.00169 μM Compound: Gefitinib	Antiproliferative activity against human HCC827 cells expressing EGFR del119 mutant assessed as inhibition in cell viability after 72 hrs by CCK8 assay Antiproliferative activity against human HCC827 cells expressing EGFR del119 mutant assessed as inhibition in cell viability after 72 hrs by CCK8 assay	[PMID: 34794818]
HCC827	IC₅₀	0.002 μM Compound: Gefitinib	Antiproliferative activity against human HCC827 cells harboring EGFR E746_A750 deletion mutant after 48 hrs by MTT assay Antiproliferative activity against human HCC827 cells harboring EGFR E746_A750 deletion mutant after 48 hrs by MTT assay	[PMID: 28236592]
HCC827	IC₅₀	0.006 μM Compound: Gefitinib	Antiproliferative activity against human HCC827 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human HCC827 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 32739648]
HCC827	IC₅₀	0.006 μM Compound: 1; Iressa	Antiproliferative activity against human HCC827 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human HCC827 cells incubated for 72 hrs by MTT assay	[PMID: 28395219]
HCC827	IC₅₀	0.006 μM Compound: Iressa	Antiproliferative activity against gefitinib-sensitive human HCC827 cells bearing EGFR del E746_A750 mutant after 72 hrs by MTT assay Antiproliferative activity against gefitinib-sensitive human HCC827 cells bearing EGFR del E746_A750 mutant after 72 hrs by MTT assay	[PMID: 24607591]
HCC827	IC₅₀	0.006 μM Compound: Gefitinib	Antiproliferative activity against human HCC827 cells expressing EGFR E746_A750 deletion mutant after 72 hrs by MTT assay Antiproliferative activity against human HCC827 cells expressing EGFR E746_A750 deletion mutant after 72 hrs by MTT assay	[PMID: 23792318]
HCC827	IC₅₀	0.006 μM Compound: gefitinib	Cytotoxicity against gefitinib-sensitive human HCC827 cells harboring EGFR E746_A740 deletion mutant assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against gefitinib-sensitive human HCC827 cells harboring EGFR E746_A740 deletion mutant assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23668441]
HCC827	IC₅₀	0.008 μM Compound: Gfb	Antiproliferative activity against human HCC827 cells harboring EGFR del E746-A750 mutant after 72 hrs by MTS assay Antiproliferative activity against human HCC827 cells harboring EGFR del E746-A750 mutant after 72 hrs by MTS assay	[PMID: 22339342]
HCC827	IC₅₀	0.0099 μM Compound: Gefitinib	Antiproliferative activity against human HCC827 cells harboring EGFR del E746 to A750 mutant assessed as decrease in cell viability after 72 hrs by MTT assay Antiproliferative activity against human HCC827 cells harboring EGFR del E746 to A750 mutant assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 28385595]
HCC827	IC₅₀	0.01 μM Compound: 1	Antiproliferative activity against human HCC827 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human HCC827 cells incubated for 72 hrs by MTT assay	[PMID: 31787359]
HCC827	IC₅₀	0.012 μM Compound: 1	Cytotoxicity against human HCC827 cells after 72 hrs by CCK-8 assay Cytotoxicity against human HCC827 cells after 72 hrs by CCK-8 assay	[PMID: 23973168]
HCC827	IC₅₀	0.013 μM Compound: 1, ZD-1839	Antiproliferative activity against human HCC827 cells by MTS assay Antiproliferative activity against human HCC827 cells by MTS assay	[PMID: 20961149]
HCC827	IC₅₀	0.013 μM Compound: Gefitinib	Antiproliferative activity against human HCC827 cells harboring EGFR E746 to A750 deletion mutant assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human HCC827 cells harboring EGFR E746 to A750 deletion mutant assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26829280]
HCC827	IC₅₀	0.041 μM Compound: Gefitinib	Cytotoxicity against human HCC827 cells expressing EGFR kinase E746 to A750 deletion mutant after 72 hrs by MTS assay Cytotoxicity against human HCC827 cells expressing EGFR kinase E746 to A750 deletion mutant after 72 hrs by MTS assay	10.1039/C2MD20078C
HCC827	IC₅₀	0.16 x 10^-2 μM Compound: ZD1839	Antiproliferative activity against human HCC827 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human HCC827 cells incubated for 72 hrs by MTT assay	[PMID: 31202990]
HCC827	IC₅₀	1.6 nM Compound: Gefitinib	Antiproliferative activity against human HCC827 cells harboring EGFR E746-A750 del mutant after 72 hrs by MTT assay Antiproliferative activity against human HCC827 cells harboring EGFR E746-A750 del mutant after 72 hrs by MTT assay	[PMID: 29421573]
HCC827	IC₅₀	12 nM Compound: gefitinib	Antiproliferative activity against human HCC827 cells after 96 hrs by MTS assay Antiproliferative activity against human HCC827 cells after 96 hrs by MTS assay	[PMID: 20550212]
HCC827	CC₅₀	26 nM Compound: Gefitinib	Cytotoxicity in human HCC827 cells assessed as reduction in cell viability incubated for 96 hrs by MTS method Cytotoxicity in human HCC827 cells assessed as reduction in cell viability incubated for 96 hrs by MTS method	[PMID: 31560541]
HCC827	IC₅₀	33 nM Compound: Gefitinib	Antiproliferative activity against human HCC827 cells after 48 hrs by MTT assay Antiproliferative activity against human HCC827 cells after 48 hrs by MTT assay	[PMID: 25937236]
HCC827	IC₅₀	33.3 nM Compound: Gefitinib	Antiproliferative activity against human HCC827 cells after 72 hrs by MTT assay Antiproliferative activity against human HCC827 cells after 72 hrs by MTT assay	[PMID: 29576272]
HCC827	IC₅₀	5.81 nM Compound: Gefitinib	Antiproliferative activity against gefitinib-sensitive human HCC827 cells harboring EGFR E746 to A750 deletion after 72 hrs by MTS assay Antiproliferative activity against gefitinib-sensitive human HCC827 cells harboring EGFR E746 to A750 deletion after 72 hrs by MTS assay	[PMID: 24053674]
HCT-116	IC₅₀	> 10 μM Compound: Gefitinib	Cytotoxicity against human HCT116 cells incubated for 72 hrs by MTT assay Cytotoxicity against human HCT116 cells incubated for 72 hrs by MTT assay	[PMID: 23116168]
HCT-116	IC₅₀	19.82 μM Compound: Gefitinib	Antiproliferative activity against human HCT116 cells assessed as inhibition of cell viability after 48 hrs by MTS assay Antiproliferative activity against human HCT116 cells assessed as inhibition of cell viability after 48 hrs by MTS assay	[PMID: 31494469]
HCT-116	IC₅₀	21.55 μM Compound: Iressa(TM)	Antiproliferative activity against human HCT116 after 18 hrs by MTT assay Antiproliferative activity against human HCT116 after 18 hrs by MTT assay	[PMID: 30826188]
HCT-116	IC₅₀	5.98 μM Compound: Gefitinib	Cytotoxicity against human HCT116 cells after 72 hrs by SRB assay Cytotoxicity against human HCT116 cells after 72 hrs by SRB assay	[PMID: 29407971]
HCT-116	IC₅₀	66.9 μM Compound: GF	Induction of apoptosis in human HCT116 cells expressing KRAS mutant assessed as depolarization of mitochondrial membrane after 24 hrs by flow cytometry Induction of apoptosis in human HCT116 cells expressing KRAS mutant assessed as depolarization of mitochondrial membrane after 24 hrs by flow cytometry	[PMID: 23063521]
HCT-116	GI₅₀	7.94 μM Compound: Gefitinib	Growth inhibition of human HCT-116 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HCT-116 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
HCT-15	GI₅₀	5.01 μM Compound: Gefitinib	Growth inhibition of human HCT-15 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HCT-15 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
HEK293	IC₅₀	420 nM Compound: Gefitinib	Inhibition of tracer 5 binding to human N-terminal nano luciferase-fused GAK expressed in HEK293 cells measured after 2 hrs by nanoBRET assay Inhibition of tracer 5 binding to human N-terminal nano luciferase-fused GAK expressed in HEK293 cells measured after 2 hrs by nanoBRET assay	[PMID: 30973735]
HEK-293T	CC₅₀	52.03 μM Compound: Gefitinib	Cytotoxicity against human 293T cells after 24 hrs by MTT assay Cytotoxicity against human 293T cells after 24 hrs by MTT assay	[PMID: 25866240]
HeLa	IC₅₀	1.48 μM Compound: Gefitinib	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 30342958]
HeLa	IC₅₀	1.52 μM Compound: Gefitinib	Antiproliferative activity against human HeLa cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HeLa cells incubated for 48 hrs by MTT assay	[PMID: 26346367]
HeLa	GI₅₀	1.52 μM Compound: Gefitinib	Antiproliferative activity against human HeLa cells after 48 hrs in presence of 10% FBS by MTT method Antiproliferative activity against human HeLa cells after 48 hrs in presence of 10% FBS by MTT method	[PMID: 27515719]
HeLa	IC₅₀	108.3 μM Compound: GF	Induction of apoptosis in human HeLa cells expressing wild type KRAS and BRAF assessed as depolarization of mitochondrial membrane after 24 hrs by flow cytometry Induction of apoptosis in human HeLa cells expressing wild type KRAS and BRAF assessed as depolarization of mitochondrial membrane after 24 hrs by flow cytometry	[PMID: 23063521]
HeLa	IC₅₀	15.4 μM Compound: Gefitinib	Antiproliferative activity against human HeLa cells after 48 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells after 48 hrs by CCK-8 assay	[PMID: 26343825]
HeLa	IC₅₀	18.3 μM Compound: Gefitinib	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 28462838]
HeLa	IC₅₀	2.26 μM Compound: Gefitinib	Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay	[PMID: 25866240]
HeLa	IC₅₀	2.67 μM Compound: Gefitinib	Antiproliferative activity against human HeLa cells assessed as growth inhibition after 24 to 48 hrs by CCK8 assay Antiproliferative activity against human HeLa cells assessed as growth inhibition after 24 to 48 hrs by CCK8 assay	[PMID: 24731281]
HeLa	IC₅₀	23.92 μM Compound: Gefitinib	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32866757]
HeLa	IC₅₀	39.32 μM Compound: Gefitinib	Antiproliferative activity against human HeLa cells by CCK8 assay Antiproliferative activity against human HeLa cells by CCK8 assay	[PMID: 34922028]
HeLa	IC₅₀	4.3 μM Compound: Gefitinib	Anticancer activity against human HeLa cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay Anticancer activity against human HeLa cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	[PMID: 29656203]
HeLa	IC₅₀	45.59 μM Compound: Gefitinib	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 20304537]
HeLa	IC₅₀	9.68 μM Compound: Gefitinib	Inhibition of Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells after 4.5 hrs beta-lactamase reporter assay Inhibition of Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells after 4.5 hrs beta-lactamase reporter assay	[PMID: 29624387]
HepG2	IC₅₀	> 10 μM Compound: Gefitinib	Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 26159483]
HepG2	IC₅₀	> 10 μM Compound: Gefitinib	Cytotoxicity against human HepG2 cells incubated for 72 hrs by MTT assay Cytotoxicity against human HepG2 cells incubated for 72 hrs by MTT assay	[PMID: 23116168]
HepG2	IC₅₀	> 50 μM Compound: Gefitinib	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 27387355]
HepG2	IC₅₀	0.12 μM Compound: Gefitinib	Antiproliferative activity against human HepG2 cells assessed as cell growth by MTT assay Antiproliferative activity against human HepG2 cells assessed as cell growth by MTT assay	[PMID: 26003342]
HepG2	IC₅₀	15.9 μM Compound: Gefitinib	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 28462838]
HepG2	IC₅₀	18.22 μM Compound: Gefitinib	Antiproliferative activity against human HepG2 cells by MTT assay Antiproliferative activity against human HepG2 cells by MTT assay	[PMID: 26560049]
HepG2	IC₅₀	18.36 μM Compound: Iressa(TM)	Antiproliferative activity against human HepG2 cells by MTT assay Antiproliferative activity against human HepG2 cells by MTT assay	[PMID: 30826188]
HepG2	IC₅₀	24.19 μM Compound: Gefitinib	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32866757]
HepG2	IC₅₀	29.79 μM Compound: Gefitinib	Antiproliferative activity against human HepG2 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells incubated for 72 hrs by MTT assay	[PMID: 31488358]
HepG2	IC₅₀	29.79 μM Compound: Gefitinib	Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 28711702]
HepG2	IC₅₀	29.79 μM Compound: 2	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 23871909]
HepG2	IC₅₀	33.9 μM Compound: Gefitinib	Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 32739648]
HepG2	IC₅₀	6.42 μM Compound: Gefitinib	Antiproliferative activity against human HepG2 cells assessed as growth inhibition after 24 to 48 hrs by CCK8 assay Antiproliferative activity against human HepG2 cells assessed as growth inhibition after 24 to 48 hrs by CCK8 assay	[PMID: 24731281]
HepG2	IC₅₀	6.42 μM Compound: Iressa	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 22727449]
HepG2	IC₅₀	6.6 μM Compound: Gefitinib	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay	[PMID: 31013087]
HepG2	IC₅₀	7.52 μM Compound: Gefitinib	Antiproliferative activity against human HepG2 cells over expressing EGFR after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells over expressing EGFR after 48 hrs by MTT assay	[PMID: 27118497]
HGC-27	IC₅₀	12.44 μM Compound: Gefitinib	Cytotoxicity against human HGC27 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HGC27 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30939352]
HL-60	IC₅₀	54.5 μM Compound: Gifitinib	Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay	[PMID: 22698782]
HN5	EC₅₀	10 nM Compound: Iressa	Antiproliferative activity against human HN5 cells overexpressing EGFR after 3 days by methylene blue staining Antiproliferative activity against human HN5 cells overexpressing EGFR after 3 days by methylene blue staining	[PMID: 19028424]
HOP-62	GI₅₀	10 μM Compound: Gefitinib	Growth inhibition of human HOP-62 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HOP-62 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
HOP-92	GI₅₀	7.94 μM Compound: Gefitinib	Growth inhibition of human HOP-92 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HOP-92 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
Hs-578T	GI₅₀	10 μM Compound: Gefitinib	Growth inhibition of human Hs-578T cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Hs-578T cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
HT-29	IC₅₀	110.3 μM Compound: GF	Induction of apoptosis in human HT-29 cells expressing BRAF mutant assessed as depolarization of mitochondrial membrane after 24 hrs by flow cytometry Induction of apoptosis in human HT-29 cells expressing BRAF mutant assessed as depolarization of mitochondrial membrane after 24 hrs by flow cytometry	[PMID: 23063521]
HT-29	IC₅₀	16.93 μM Compound: Gefitinib	Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 20304537]
HT-29	IC₅₀	3.36 μM Compound: Iressa	Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 22727449]
HT-29	IC₅₀	3.63 μM Compound: 3	Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation under normoxia conditions after 72 hrs by SRB assay Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation under normoxia conditions after 72 hrs by SRB assay	[PMID: 25468044]
HT-29	IC₅₀	3.63 μM Compound: Gefitinib	Cytotoxicity against human HT-29 cells after 72 hrs under normoxia conditions by SRB assay Cytotoxicity against human HT-29 cells after 72 hrs under normoxia conditions by SRB assay	[PMID: 25462282]
HT-29	GI₅₀	3.98 μM Compound: Gefitinib	Growth inhibition of human HT-29 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human HT-29 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
HT-29	IC₅₀	5.21 μM Compound: 3	Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation under hypoxia conditions after 72 hrs by SRB assay Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation under hypoxia conditions after 72 hrs by SRB assay	[PMID: 25468044]
HT-29	IC₅₀	5.21 μM Compound: Gefitinib	Cytotoxicity against human HT-29 cells after 72 hrs under hypoxia conditions by SRB assay Cytotoxicity against human HT-29 cells after 72 hrs under hypoxia conditions by SRB assay	[PMID: 25462282]
HT-29	IC₅₀	8.19 μM Compound: Gefitinib	Cytotoxicity against human HT-29 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 26451770]
HT-29	IC₅₀	8.19 μM Compound: Gefitinib	Antiproliferative activity against non-special gene type human HT-29 cells after 48 hrs by SRB assay Antiproliferative activity against non-special gene type human HT-29 cells after 48 hrs by SRB assay	[PMID: 28366268]
HT-29	IC₅₀	9.8 μM Compound: Iressa	Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 20056425]
Huh-7	IC₅₀	> 10 μM Compound: Gefitinib	Cytotoxicity against human HuH7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human HuH7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 26159483]
HuTu80	ED₅₀	0.77 μg/mL Compound: Gefitinib	Cytotoxicity against Homo sapiens (human) HuTu 80 cells after 72 hr by MTT assay Cytotoxicity against Homo sapiens (human) HuTu 80 cells after 72 hr by MTT assay	10.1007/s00044-012-0309-2
HUVEC	GI₅₀	13 μM Compound: Gefitinib	Growth inhibition of HUVEC after 48 hrs by MTT assay Growth inhibition of HUVEC after 48 hrs by MTT assay	[PMID: 28291344]
IGROV-1	GI₅₀	0.2 μM Compound: Gefitinib	Growth inhibition of human IGROV-1 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human IGROV-1 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
K562	IC₅₀	> 10 μM Compound: Gefitinib	Cytotoxicity against human K562 cells after 48 hrs by CellTiter-Glo assay Cytotoxicity against human K562 cells after 48 hrs by CellTiter-Glo assay	[PMID: 24900594]
K562	IC₅₀	14.27 μM Compound: Gefitinib	Cytotoxicity against human K562 cells after 48 hrs by MTT assay Cytotoxicity against human K562 cells after 48 hrs by MTT assay	[PMID: 35247755]
K562	GI₅₀	2.51 μM Compound: Gefitinib	Growth inhibition of human K562 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human K562 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
K562	IC₅₀	9.36 μM Compound: ZD-1839, IRESSA	Cytotoxicity against human K562 cells after 96 hrs by MTT assay Cytotoxicity against human K562 cells after 96 hrs by MTT assay	[PMID: 18313807]
K562/A02	IC₅₀	32.35 μM Compound: Gefitinib	Cytotoxicity against human K562/A02 cells after 48 hrs by MTT assay Cytotoxicity against human K562/A02 cells after 48 hrs by MTT assay	[PMID: 35247755]
KB	IC₅₀	0.025 μM Compound: Gefitinib	Inhibition of EGFR in human KB cells assessed as reduction in EGF-stimulated EGFR phosphorylation preincubated for 1 hr followed by EGF stimulation and measured after 6 mins by ELISA Inhibition of EGFR in human KB cells assessed as reduction in EGF-stimulated EGFR phosphorylation preincubated for 1 hr followed by EGF stimulation and measured after 6 mins by ELISA	[PMID: 32139324]
KB	IC₅₀	0.025 μM Compound: Gefitinib, Iressa	Inhibition of EGF-stimulated autophosphorylation of EGFR in human KB cells incubated for 1 hr prior to EGF challenge measured after 6 mins by ELISA Inhibition of EGF-stimulated autophosphorylation of EGFR in human KB cells incubated for 1 hr prior to EGF challenge measured after 6 mins by ELISA	[PMID: 24411123]
KB	ED₅₀	0.33 μg/mL Compound: Gefitinib	Cytotoxicity against Homo sapiens (human) KB cells after 72 hr by MTT assay Cytotoxicity against Homo sapiens (human) KB cells after 72 hr by MTT assay	10.1007/s00044-012-0309-2
KB	IC₅₀	2.8 μM Compound: 1, Iressa	Antiproliferative activity against human KB cells expressing EGFR and SRC by MTT assay Antiproliferative activity against human KB cells expressing EGFR and SRC by MTT assay	[PMID: 22818848]
KB	IC₅₀	54 nM Compound: 1	Antiproliferative activity against EGF-stimulated human KB cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against EGF-stimulated human KB cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 33540357]
KM12	GI₅₀	7.94 μM Compound: Gefitinib	Growth inhibition of human KM12 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human KM12 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
L02	IC₅₀	> 10 μM Compound: Gfb	Antiproliferative activity against human HL7702 cells expressing wilt type EGFR after 72 hrs by MTS assay Antiproliferative activity against human HL7702 cells expressing wilt type EGFR after 72 hrs by MTS assay	[PMID: 22339342]
L02	IC₅₀	10.08 μM Compound: 4	Cytotoxicity against human L02 cells assessed as inhibition of cell growth measured by CCK8 assay Cytotoxicity against human L02 cells assessed as inhibition of cell growth measured by CCK8 assay	[PMID: 34216747]
L02	IC₅₀	13.26 μM Compound: Gefitinib	Cytotoxicity against human HL7702 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HL7702 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32866757]
L02	IC₅₀	19.8 μM Compound: Gefitinib	Cytotoxicity against human LO2 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human LO2 cells assessed as reduction in cell viability by MTT assay	[PMID: 31013087]
L02	IC₅₀	33.17 μM Compound: Gefitinib	Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33640672]
L02	IC₅₀	45.31 μM Compound: Gefitinib	Cytotoxicity against human L02 cells by CCK8 assay Cytotoxicity against human L02 cells by CCK8 assay	[PMID: 34922028]
L02	IC₅₀	55.08 μM Compound: Gefitinib	Cytotoxicity against human HL7702 cells expressing wild type EGFR after 72 hrs by MTS assay Cytotoxicity against human HL7702 cells expressing wild type EGFR after 72 hrs by MTS assay	10.1039/C2MD20078C
L02	IC₅₀	7.14 μM Compound: Gefitinib	Cytotoxicity against human L0-2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Cytotoxicity against human L0-2 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32402937]
L132	ED₅₀	> 1 μg/mL Compound: Gefitinib	Cytotoxicity against Homo sapiens (human) L-132 cells after 72 hr by MTT assay Cytotoxicity against Homo sapiens (human) L-132 cells after 72 hr by MTT assay	10.1007/s00044-012-0309-2
L929	IC₅₀	1.98 μM Compound: Gefitinib	Cytotoxicity against mouse L929 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against mouse L929 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 30508379]
LoVo	IC₅₀	0.062 μM Compound: 1	Inhibition of wild type EGFR phosphorylation in human LoVo cells after 2 hrs by fluorescence assay Inhibition of wild type EGFR phosphorylation in human LoVo cells after 2 hrs by fluorescence assay	[PMID: 23930994]
LOX IMVI	GI₅₀	7.94 μM Compound: Gefitinib	Growth inhibition of human LOX IMVI cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human LOX IMVI cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
Macrophage	CC₅₀	280.6 μM Compound: Gefitinib	Antiproliferative activity against human macrophages assessed as alteration in cell morphology after 24 hrs by CCK8 assay Antiproliferative activity against human macrophages assessed as alteration in cell morphology after 24 hrs by CCK8 assay	[PMID: 24731281]
MCF-10A	IC₅₀	30 μM Compound: Gefitinib	Cytotoxicity against human MCF10A cells after 72 hrs by MTT assay Cytotoxicity against human MCF10A cells after 72 hrs by MTT assay	[PMID: 25198997]
MCF7	IC₅₀	> 100 μM Compound: Gefitinib	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay	[PMID: 31488358]
MCF7	GI₅₀	> 30 μM Compound: Gefitinib	Growth inhibition of human MCF7 cells after 48 hrs by MTT assay Growth inhibition of human MCF7 cells after 48 hrs by MTT assay	[PMID: 30447889]
MCF7	EC₅₀	> 50 μM Compound: Gefitinib	Antiproliferative activity against human ER-negative MCF7 cells after 24 hrs by MTT assay Antiproliferative activity against human ER-negative MCF7 cells after 24 hrs by MTT assay	[PMID: 25198997]
MCF7	ED₅₀	0.89 μg/mL Compound: Gefitinib	Cytotoxicity against Homo sapiens (human) MCF7 cells after 72 hr by MTT assay Cytotoxicity against Homo sapiens (human) MCF7 cells after 72 hr by MTT assay	10.1007/s00044-012-0309-2
MCF7	IC₅₀	1 μM Compound: 1	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 18771819]
MCF7	IC₅₀	1.1 μM Compound: Gefitinib	Inhibition of BCRP expressed in MCF7 MX cells by Hoechst 33342 staining Inhibition of BCRP expressed in MCF7 MX cells by Hoechst 33342 staining	[PMID: 19932960]
MCF7	GI₅₀	10 μM Compound: Gefitinib	Growth inhibition of human MCF7 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human MCF7 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
MCF7	IC₅₀	10.29 μM Compound: Gefitinib	Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 25866240]
MCF7	IC₅₀	12.05 μM Compound: Gefitinib, Iressa	Antiproliferative activity against human MCF7 cells overexpressing EGFR gene after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells overexpressing EGFR gene after 48 hrs by MTT assay	[PMID: 22119130]
MCF7	IC₅₀	12.05 μM Compound: Gefitinib	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 28711702]
MCF7	IC₅₀	13.1 μM Compound: Gefitinib	Antiproliferative activity against human MCF7 cells overexpressing EGFR assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells overexpressing EGFR assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26829280]
MCF7	IC₅₀	13.24 μM Compound: Gefitinib	Antiproliferative activity against human MCF7 cells by CCK8 assay Antiproliferative activity against human MCF7 cells by CCK8 assay	[PMID: 34922028]
MCF7	IC₅₀	17.83 μM Compound: Gefitinib	Antiproliferative activity against human MCF7 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human MCF7 cells after 48 hrs by CCK-8 assay	[PMID: 26343825]
MCF7	IC₅₀	2.97 μM Compound: Gefitinib	Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth incubated for 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth incubated for 24 hrs by MTT assay	[PMID: 31431361]
MCF7	IC₅₀	20.68 μM Compound: Iressa(TM)	Antiproliferative activity against human MCF7 after 18 hrs by MTT assay Antiproliferative activity against human MCF7 after 18 hrs by MTT assay	[PMID: 30826188]
MCF7	GI₅₀	20.8 μM Compound: Gefitinib	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 27993518]
MCF7	IC₅₀	23.52 μM Compound: Iressa(TM)	Antiproliferative activity against human MCF7 by MTT assay Antiproliferative activity against human MCF7 by MTT assay	[PMID: 30826188]
MCF7	IC₅₀	25.37 μM Compound: Gefitinib	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 27132165]
MCF7	IC₅₀	26.7 μM Compound: Gefitinib	Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay	[PMID: 29407971]
MCF7	IC₅₀	3.3 μM Compound: Gefitinib	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 26159483]
MCF7	IC₅₀	3.57 μM Compound: Gefitinib	Cytotoxicity against human MCF7 cells incubated for 2 to 4 hrs by MTT assay Cytotoxicity against human MCF7 cells incubated for 2 to 4 hrs by MTT assay	[PMID: 33771586]
MCF7	EC₅₀	35 μM Compound: Gefitinib	Antiproliferative activity against human ER-negative MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human ER-negative MCF7 cells after 72 hrs by MTT assay	[PMID: 25198997]
MCF7	IC₅₀	6.26 μM Compound: Gefitinib	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 30503938]
MCF7	IC₅₀	6.71 μM Compound: Gefitinib	Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay	[PMID: 26346367]
MCF7	GI₅₀	6.71 μM Compound: Gefitinib	Antiproliferative activity against human MCF7 cells after 48 hrs in presence of 10% FBS by MTT method Antiproliferative activity against human MCF7 cells after 48 hrs in presence of 10% FBS by MTT method	[PMID: 27515719]
MCF7	IC₅₀	6.77 μM Compound: Gefitinib	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 30342958]
MCF7	IC₅₀	69.16 μM Compound: Gefitinib	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 20304537]
MCF7	IC₅₀	7.34 μM Compound: Gefitinib	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30939352]
MDA-MB-231	IC₅₀	> 10 μM Compound: Gefitinib	Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by MTT assay	[PMID: 23116168]
MDA-MB-231	EC₅₀	> 50 μM Compound: Gefitinib	Antiproliferative activity against human ER-positive MDA-MB-231 cells after 24 hrs by MTT assay Antiproliferative activity against human ER-positive MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 25198997]
MDA-MB-231	GI₅₀	12.6 μM Compound: Gefitinib	Growth inhibition of human MDA-MB-231/ATCC cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human MDA-MB-231/ATCC cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
MDA-MB-231	GI₅₀	14.2 μM Compound: Gefitinib	Growth inhibition of human MDA-MB-231 cells after 48 hrs by MTT assay Growth inhibition of human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 28291344]
MDA-MB-231	IC₅₀	14.52 μM Compound: Gefitinib	Antiproliferative activity against human MDA-MB-231 cells by CCK8 assay Antiproliferative activity against human MDA-MB-231 cells by CCK8 assay	[PMID: 34922028]
MDA-MB-231	EC₅₀	25 μM Compound: Gefitinib	Antiproliferative activity against human ER-positive MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human ER-positive MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 25198997]
MDA-MB-231	IC₅₀	28.3 μM Compound: Gefitinib	Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	[PMID: 29656203]
MDA-MB-231	IC₅₀	36.61 μM Compound: ZD-1839, IRESSA	Cytotoxicity against human MDA-MB-231 cells after 96 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 96 hrs by MTT assay	[PMID: 18313807]
MDA-MB-231	IC₅₀	37.82 μM Compound: Gefitinib	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 27132165]
MDA-MB-231	IC₅₀	4.1 μM Compound: Gefitinib	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 26159483]
MDA-MB-231	IC₅₀	6.85 μM Compound: Gefitinib	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 32739648]
MDA-MB-231	IC₅₀	7.12 μM Compound: Gefitinib	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 34192644]
MDA-MB-231	IC₅₀	8.72 μM Compound: Gefitinib	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30939352]
MDA-MB-468	GI₅₀	0.01 μM Compound: Gefitinib	Growth inhibition of human MDA-MB-468 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human MDA-MB-468 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
MDA-MB-468	GI₅₀	25.5 μM Compound: Gefitinib	Growth inhibition of EGFR over-expressing human MDA-MB-468 cells after 48 hrs by MTT assay Growth inhibition of EGFR over-expressing human MDA-MB-468 cells after 48 hrs by MTT assay	[PMID: 30447889]
MDA-MB-468	IC₅₀	3.9 μM Compound: Gefitinib	Cytotoxicity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 26159483]
MDA-MB-468	GI₅₀	9.7 μM Compound: Gefitinib	Cytotoxicity against gefitinib-resistant human MDA-MB-468 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against gefitinib-resistant human MDA-MB-468 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 27993518]
MDCK	IC₅₀	1.26 μM Compound: Gefitinib	Inhibition of BCRP expressed in MDCK cells by pheophorbide A assay Inhibition of BCRP expressed in MDCK cells by pheophorbide A assay	[PMID: 19932960]
MDCK	GI₅₀	1.45 μM Compound: Gefitinib, Iressa	Cytotoxicity against MDCK cells after 72 hrs by MTT assay Cytotoxicity against MDCK cells after 72 hrs by MTT assay	[PMID: 24184213]
MDCK-II	GI₅₀	1.36 μM Compound: Gefitinib	Growth inhibition of MDCK2 cells harboring GFP-fused human ABCG2 after 72 hrs by MTT assay Growth inhibition of MDCK2 cells harboring GFP-fused human ABCG2 after 72 hrs by MTT assay	[PMID: 30390439]
MDCK-II	GI₅₀	2.1 μM Compound: Gefitinib	Growth inhibition of MDCK2 cells after 72 hrs by MTT assay Growth inhibition of MDCK2 cells after 72 hrs by MTT assay	[PMID: 30390439]
MDCK-II	IC₅₀	3.19 μM Compound: Gefitinib, Iressa	Inhibition of human BCRP expressed in MDCK2 cells assessed as Hoechst 33342 accumulation treated 30 mins before Hoechst 33342 addition measured up to 120 mins by fluorescence assay Inhibition of human BCRP expressed in MDCK2 cells assessed as Hoechst 33342 accumulation treated 30 mins before Hoechst 33342 addition measured up to 120 mins by fluorescence assay	[PMID: 24184213]
MGC-803	IC₅₀	26.19 μM Compound: Gef	Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 32827851]
MGC-803	IC₅₀	26.19 μM Compound: Gefitinib	Antiproliferative activity against human MGC803 cells by MTT assay Antiproliferative activity against human MGC803 cells by MTT assay	[PMID: 26560049]
MGC-803	IC₅₀	8.19 μM Compound: Gefitinib	Antiproliferative activity against human MGC-803 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human MGC-803 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 34192644]
MGC-803	IC₅₀	8.82 μM Compound: Gefitinib	Cytotoxicity against human MGC803 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MGC803 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30939352]
MIA PaCa-2	ED₅₀	0.51 μg/mL Compound: Gefitinib	Cytotoxicity against Homo sapiens (human) MIAPaCa2 cells after 72 hr by MTT assay Cytotoxicity against Homo sapiens (human) MIAPaCa2 cells after 72 hr by MTT assay	10.1007/s00044-012-0309-2
MIA PaCa-2	IC₅₀	45.8 μM Compound: Gefitinib	Cytotoxicity against human MIAPaCa2 cells after 4 to 5 days by MTT assay Cytotoxicity against human MIAPaCa2 cells after 4 to 5 days by MTT assay	[PMID: 20466555]
MKN-45	IC₅₀	12.29 μM Compound: Gefitinib	Cytotoxicity against human MKN45 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human MKN45 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29496411]
MOLT-4	ED₅₀	> 1 μg/mL Compound: Gefitinib	Cytotoxicity against Homo sapiens (human) MOLT4 cells after 72 hr by MTT assay Cytotoxicity against Homo sapiens (human) MOLT4 cells after 72 hr by MTT assay	10.1007/s00044-012-0309-2
MOLT-4	IC₅₀	15.02 μM Compound: ZD-1839, IRESSA	Cytotoxicity against human MOLT4 cells after 96 hrs by MTT assay Cytotoxicity against human MOLT4 cells after 96 hrs by MTT assay	[PMID: 18313807]
MOLT-4	GI₅₀	3.98 μM Compound: Gefitinib	Growth inhibition of human MOLT4 cells incubated for 48 hrs by SRB assay Growth inhibition of human MOLT4 cells incubated for 48 hrs by SRB assay	[PMID: 31023512]
NCI-H1299	IC₅₀	3.02 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1299 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human NCI-H1299 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 32739648]
NCI-H1299	IC₅₀	4.05 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1299 cells expressing wild type EGFR assessed as inhibition in cell viability after 72 hrs by CCK8 assay Antiproliferative activity against human NCI-H1299 cells expressing wild type EGFR assessed as inhibition in cell viability after 72 hrs by CCK8 assay	[PMID: 34794818]
NCI-H1299	IC₅₀	40 μM Compound: Gefitinib	Cytotoxicity against human NCI-H1299 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay Cytotoxicity against human NCI-H1299 cells assessed as cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 35696863]
NCI-H1299	IC₅₀	6.56 μM Compound: Cpd G	Antiproliferative activity against human NCI-H1299 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay Antiproliferative activity against human NCI-H1299 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK8 assay	[PMID: 34038131]
NCI-H1650	IC₅₀	2.64 μM Compound: Gefitinib	Antiproliferative activity against human H1650 cells by CCK8 assay Antiproliferative activity against human H1650 cells by CCK8 assay	[PMID: 34922028]
NCI-H1975	IC₅₀	> 10 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells incubated for 72 hrs by MTS assay Antiproliferative activity against human NCI-H1975 cells incubated for 72 hrs by MTS assay	[PMID: 31718182]
NCI-H1975	IC₅₀	> 10 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells harbouring EGFR L858R/T790M/C797S mutant incubated for 72 hrs by MTS assay Antiproliferative activity against human NCI-H1975 cells harbouring EGFR L858R/T790M/C797S mutant incubated for 72 hrs by MTS assay	[PMID: 31718182]
NCI-H1975	IC₅₀	> 10 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M mutant assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M mutant assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 32139324]
NCI-H1975	IC₅₀	> 10 μM Compound: Iressa	Cytotoxicity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 27524310]
NCI-H1975	IC₅₀	> 10 μM Compound: Gefitinib, Iressa	Cytotoxicity against human NCI-H1975 cells expressing EGFR L858R/T790M mutant after 72 hrs by MTT assay Cytotoxicity against human NCI-H1975 cells expressing EGFR L858R/T790M mutant after 72 hrs by MTT assay	[PMID: 24411123]
NCI-H1975	IC₅₀	> 10000 nM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells after 72 hrs by MTT assay	[PMID: 29576272]
NCI-H1975	IC₅₀	> 10000 nM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells harboring EGFR T790M/L858R double mutant after 72 hrs by EZ-Cytox assay Antiproliferative activity against human NCI-H1975 cells harboring EGFR T790M/L858R double mutant after 72 hrs by EZ-Cytox assay	[PMID: 30554954]
NCI-H1975	IC₅₀	1.23 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells over expressing EGFR after 48 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells over expressing EGFR after 48 hrs by MTT assay	[PMID: 27118497]
NCI-H1975	IC₅₀	1.71 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells expressing EGFR T790M/L858R mutant assessed as inhibition in cell viability after 72 hrs by CCK-8 assay Antiproliferative activity against human NCI-H1975 cells expressing EGFR T790M/L858R mutant assessed as inhibition in cell viability after 72 hrs by CCK-8 assay	[PMID: 34794818]
NCI-H1975	IC₅₀	10 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells after 48 hrs by Celltiter-Glo assay Antiproliferative activity against human NCI-H1975 cells after 48 hrs by Celltiter-Glo assay	[PMID: 25409491]
NCI-H1975	IC₅₀	10 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells harbouring EGFR L858R/T790M double mutant assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells harbouring EGFR L858R/T790M double mutant assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31446247]
NCI-H1975	IC₅₀	10 μM Compound: Gefitinib	Cytotoxicity against human NCI-H1975 cells incubated for 72 hrs by MTT assay Cytotoxicity against human NCI-H1975 cells incubated for 72 hrs by MTT assay	[PMID: 23116168]
NCI-H1975	IC₅₀	10.48 μM Compound: Gefitinib	Inhibition of EGFR L858R/T790M mutant in human NCI-H1975 cells assessed as growth inhibition after 48 hrs by MTT assay Inhibition of EGFR L858R/T790M mutant in human NCI-H1975 cells assessed as growth inhibition after 48 hrs by MTT assay	[PMID: 24900594]
NCI-H1975	EC₅₀	10.7 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells harboring EGFR-L858R/T790M double mutant incubated for 96 hrs measured on day 5 by CellTiterGlo assay Antiproliferative activity against human NCI-H1975 cells harboring EGFR-L858R/T790M double mutant incubated for 96 hrs measured on day 5 by CellTiterGlo assay	[PMID: 28853575]
NCI-H1975	IC₅₀	10.78 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33640672]
NCI-H1975	IC₅₀	10.89 μM Compound: 1	Antiproliferative activity against human NCI-H1975 cells harboring L858R/T790M double mutant after 48 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells harboring L858R/T790M double mutant after 48 hrs by MTT assay	[PMID: 27634676]
NCI-H1975	IC₅₀	10.89 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 32739648]
NCI-H1975	IC₅₀	10.89 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells harboring EGFR T790M/L858R double mutant after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells harboring EGFR T790M/L858R double mutant after 72 hrs by MTT assay	[PMID: 30471829]
NCI-H1975	EC₅₀	11 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant assessed as growth inhibition after 96 hrs by CellTiter-Glo assay Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant assessed as growth inhibition after 96 hrs by CellTiter-Glo assay	[PMID: 28603991]
NCI-H1975	IC₅₀	11.39 μM Compound: Gefitinib	Cytotoxicity against gefitinib-resistant human NCI-H1975 cells expressing EGFR L858R/T790M double mutant assessed as growth inhibition incubated for 1 hr prior to EGF challenge measured after 72 hrs by luciferase reporter gene assay Cytotoxicity against gefitinib-resistant human NCI-H1975 cells expressing EGFR L858R/T790M double mutant assessed as growth inhibition incubated for 1 hr prior to EGF challenge measured after 72 hrs by luciferase reporter gene assay	10.1039/C3MD00118K
NCI-H1975	IC₅₀	12.7 μM Compound: ZD1839	Antiproliferative activity against human NCI-H1975 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells incubated for 72 hrs by MTT assay	[PMID: 31202990]
NCI-H1975	IC₅₀	12.7 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant after 72 hrs by MTT assay	[PMID: 29421573]
NCI-H1975	IC₅₀	12.7 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M mutant after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M mutant after 72 hrs by MTT assay	[PMID: 28711703]
NCI-H1975	IC₅₀	13.13 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells harboring EGFR T790M/L858R double mutant assessed as decrease in cell viability after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells harboring EGFR T790M/L858R double mutant assessed as decrease in cell viability after 72 hrs by MTT assay	[PMID: 28385595]
NCI-H1975	IC₅₀	13.98 μM Compound: Gefitinib	Inhibition of EGFR L858R/T790M mutant in human NCI-H1975 cells assessed as inhibition of EGF-mediated autophosphorylation incubated for 30 mins prior to EGF challenge by cytoblot assay Inhibition of EGFR L858R/T790M mutant in human NCI-H1975 cells assessed as inhibition of EGF-mediated autophosphorylation incubated for 30 mins prior to EGF challenge by cytoblot assay	10.1039/C3MD00118K
NCI-H1975	IC₅₀	13613 nM Compound: Gefitinib	Antiproliferative activity against gefitinib-resistant human NCI-H1975 cells expressing T790M/L858R mutation after 72 hrs by MTS assay Antiproliferative activity against gefitinib-resistant human NCI-H1975 cells expressing T790M/L858R mutation after 72 hrs by MTS assay	[PMID: 24053674]
NCI-H1975	IC₅₀	14.38 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells expressing L858R/T790M mutant EGFR after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells expressing L858R/T790M mutant EGFR after 72 hrs by MTT assay	[PMID: 27387355]
NCI-H1975	IC₅₀	14707 nM Compound: Gefitinib	Antiproliferative activity against human gefitinib-resistant NCI-H1975 cells after 48 hrs by MTT assay Antiproliferative activity against human gefitinib-resistant NCI-H1975 cells after 48 hrs by MTT assay	[PMID: 25937236]
NCI-H1975	IC₅₀	15.35 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant after 48 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant after 48 hrs by MTT assay	[PMID: 28236592]
NCI-H1975	IC₅₀	17.79 μM Compound: Gefitinib	Antiproliferative activity against human H1975 cells harboring EGFR L858R/T790M double mutant assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human H1975 cells harboring EGFR L858R/T790M double mutant assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32402937]
NCI-H1975	IC₅₀	18.19 μM Compound: Gefitinib	Cytotoxicity against human NCI-H1975 cells expressing EGFR kinase L858R/T790M double mutant after 72 hrs by MTS assay Cytotoxicity against human NCI-H1975 cells expressing EGFR kinase L858R/T790M double mutant after 72 hrs by MTS assay	10.1039/C2MD20078C
NCI-H1975	CC₅₀	18755 nM Compound: Gefitinib	Cytotoxicity in human NCI-H1975 cells assessed as reduction in cell viability incubated for 96 hrs by MTS method Cytotoxicity in human NCI-H1975 cells assessed as reduction in cell viability incubated for 96 hrs by MTS method	[PMID: 31560541]
NCI-H1975	IC₅₀	26.9 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 26829280]
NCI-H1975	IC₅₀	3.3 μM Compound: 1	Inhibition of EGFR L858R/T970M double mutant phosphorylation in human NCI-H1975 cells after 2 hrs by fluorescence assay Inhibition of EGFR L858R/T970M double mutant phosphorylation in human NCI-H1975 cells after 2 hrs by fluorescence assay	[PMID: 23930994]
NCI-H1975	IC₅₀	4.691 μM Compound: 1; Iressa	Antiproliferative activity against human NCI-H1975 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells incubated for 72 hrs by MTT assay	[PMID: 28395219]
NCI-H1975	IC₅₀	4.81 μM Compound: Gefitinib	Growth inhibition of human NCI-H1975 cells incubated for 5 days by SRB assay Growth inhibition of human NCI-H1975 cells incubated for 5 days by SRB assay	[PMID: 32145644]
NCI-H1975	IC₅₀	44.6 μM Compound: 1	Antiproliferative activity against human NCI-H1975 cells expressing EGFR L858R/T790M mutant assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human NCI-H1975 cells expressing EGFR L858R/T790M mutant assessed as inhibition of cell growth by MTT assay	[PMID: 31869655]
NCI-H1975	IC₅₀	6.5 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells measured after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells measured after 72 hrs by MTT assay	[PMID: 31757525]
NCI-H1975	IC₅₀	6.917 μM Compound: Iressa	Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M mutant after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M mutant after 72 hrs by MTT assay	[PMID: 24607591]
NCI-H1975	IC₅₀	6.917 μM Compound: gefitinib	Cytotoxicity against gefitinib-resistant human NCI-H1975 cells harboring EGFR L858R/T90M double mutant assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against gefitinib-resistant human NCI-H1975 cells harboring EGFR L858R/T90M double mutant assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23668441]
NCI-H1975	IC₅₀	7184 nM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer glo luminescent cell viability assay Antiproliferative activity against human NCI-H1975 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer glo luminescent cell viability assay	[PMID: 29523467]
NCI-H1975	IC₅₀	78.7 μM Compound: Gefitinib	Antiproliferative activity against gefitinib-resistant human NCI-H1975 cells measured after 72 hrs by MTT assay Antiproliferative activity against gefitinib-resistant human NCI-H1975 cells measured after 72 hrs by MTT assay	[PMID: 31757525]
NCI-H1975	IC₅₀	8.26 μM Compound: 1	Antiproliferative activity against human NCI-H1975 cells after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells after 72 hrs by MTT assay	[PMID: 20151670]
NCI-H1975	IC₅₀	8.58 μM Compound: Gefitinib	Cytotoxicity against human NCI-H1975 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human NCI-H1975 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29496411]
NCI-H1975	IC₅₀	8.589 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells expressing EGFR L858R/T790M mutant after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells expressing EGFR L858R/T790M mutant after 72 hrs by MTT assay	[PMID: 23792318]
NCI-H1975	IC₅₀	8.71 μM Compound: Gefitinib	Antiproliferative activity against gefitinib-resistant human NCI-H1975 cells harboring EGFR T790M/L858R double mutant after 72 hrs by MTT assay Antiproliferative activity against gefitinib-resistant human NCI-H1975 cells harboring EGFR T790M/L858R double mutant after 72 hrs by MTT assay	[PMID: 26451770]
NCI-H1975	IC₅₀	8.71 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant after 48 hrs by SRB assay Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M double mutant after 48 hrs by SRB assay	[PMID: 28366268]
NCI-H1975	IC₅₀	9.02 μM Compound: Gfb	Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M mutant after 72 hrs by MTS assay Antiproliferative activity against human NCI-H1975 cells harboring EGFR L858R/T790M mutant after 72 hrs by MTS assay	[PMID: 22339342]
NCI-H1975	IC₅₀	9.1 μM Compound: 1	Growth inhibition of human NCI-H1975 cells after 72 hrs by MTT assay Growth inhibition of human NCI-H1975 cells after 72 hrs by MTT assay	[PMID: 30472599]
NCI-H1975	IC₅₀	9.2 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H1975 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 34192644]
NCI-H1993	IC₅₀	0.1 μM Compound: Gef	Antiproliferative activity against human NCI-H1993 cells after 3 days by SRB assay Antiproliferative activity against human NCI-H1993 cells after 3 days by SRB assay	[PMID: 21916433]
NCI-H1993	IC₅₀	20 μM Compound: Gef	Antiproliferative activity against gefitinib resistant human NCI-H1993 cells after 3 days by SRB assay Antiproliferative activity against gefitinib resistant human NCI-H1993 cells after 3 days by SRB assay	[PMID: 21916433]
NCI-H226	GI₅₀	15.9 μM Compound: Gefitinib	Growth inhibition of human NCI-H226 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H226 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
NCI-H23	IC₅₀	1.02 μM Compound: Gefitinib	Cytotoxicity against human NCI-H23 cells assessed as reduction in cell viability after 46 hrs by MTT assay Cytotoxicity against human NCI-H23 cells assessed as reduction in cell viability after 46 hrs by MTT assay	[PMID: 29138027]
NCI-H23	GI₅₀	15.9 μM Compound: Gefitinib	Growth inhibition of human NCI-H23 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H23 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
NCI-H292	IC₅₀	0.02 μM Compound: Gef	Antiproliferative activity against human NCI-H292 cells after 3 days by SRB assay Antiproliferative activity against human NCI-H292 cells after 3 days by SRB assay	[PMID: 21916433]
NCI-H292	IC₅₀	0.12 μM Compound: Gefitinib	Cytotoxicity against human NCI-H292 cells incubated for 72 hrs by MTT assay Cytotoxicity against human NCI-H292 cells incubated for 72 hrs by MTT assay	[PMID: 23116168]
NCI-H292	IC₅₀	0.19 μM Compound: Gefitinib	Cytotoxicity against human NCI-H292 cells after 72 hrs by SRB assay Cytotoxicity against human NCI-H292 cells after 72 hrs by SRB assay	[PMID: 25215856]
NCI-H292	IC₅₀	0.41 μM Compound: Gef	Antiproliferative activity against gefitinib resistant human NCI-H292 cells after 3 days by SRB assay Antiproliferative activity against gefitinib resistant human NCI-H292 cells after 3 days by SRB assay	[PMID: 21916433]
NCI-H322M	GI₅₀	0.08 μM Compound: Gefitinib	Growth inhibition of human NCI-H322M cells incubated for 48 hrs by SRB assay Growth inhibition of human NCI-H322M cells incubated for 48 hrs by SRB assay	[PMID: 31023512]
NCI-H322M	GI₅₀	0.08 μM Compound: Gefitinib	Growth inhibition of human NCI-H322M cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H322M cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
NCI-H3255	IC₅₀	0.863 μM Compound: Gefitinib	Growth inhibition of human NCI-H3255 cells harbouring EGFR L858R mutant incubated for 72 hrs by CCK8 assay Growth inhibition of human NCI-H3255 cells harbouring EGFR L858R mutant incubated for 72 hrs by CCK8 assay	[PMID: 35880853]
NCI-H358	IC₅₀	14.66 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H358 cells assessed as viable cells after 48 hrs by CCK8 assay Antiproliferative activity against human NCI-H358 cells assessed as viable cells after 48 hrs by CCK8 assay	[PMID: 26879314]
NCI-H358	IC₅₀	5.68 μM Compound: Gefitinib	Antiproliferative activity against human NCI-H358 cells assessed as reduction in cell viability after 48 hrs by cck8 assay Antiproliferative activity against human NCI-H358 cells assessed as reduction in cell viability after 48 hrs by cck8 assay	[PMID: 27234887]
NCI-H460	IC₅₀	21 μM Compound: Gefitinib	Cytotoxicity against human H460 cells after 72 hrs by SRB assay Cytotoxicity against human H460 cells after 72 hrs by SRB assay	[PMID: 25215856]
NCI-H460	IC₅₀	3.02 μM Compound: Gefitinib	Antiproliferative activity against human H460 cells by CCK8 assay Antiproliferative activity against human H460 cells by CCK8 assay	[PMID: 34922028]
NCI-H460	IC₅₀	5.59 μM Compound: Iressa	Cytotoxicity against human H460 cells after 72 hrs by MTT assay Cytotoxicity against human H460 cells after 72 hrs by MTT assay	[PMID: 22727449]
NCI-H460	GI₅₀	6.31 μM Compound: Gefitinib	Growth inhibition of human NCI-H460 cells incubated for 48 hrs by SRB assay Growth inhibition of human NCI-H460 cells incubated for 48 hrs by SRB assay	[PMID: 31023512]
NCI-H460	GI₅₀	6.31 μM Compound: Gefitinib	Growth inhibition of human NCI-H460 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H460 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
NCI-H522	GI₅₀	6.31 μM Compound: Gefitinib	Growth inhibition of human NCI-H522 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human NCI-H522 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
NCI-H661	IC₅₀	31.06 μM Compound: Gefitinib	Cytotoxicity against human NCI-H661 cells after 4 to 5 days by MTT assay Cytotoxicity against human NCI-H661 cells after 4 to 5 days by MTT assay	[PMID: 20466555]
NCI-N87	IC₅₀	1 μM Compound: Gefitinib	Antiproliferative activity against human NCI-N87 cells overexpressing HER2 assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human NCI-N87 cells overexpressing HER2 assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 32139324]
NCI-N87	IC₅₀	1 μM Compound: Iressa	Cytotoxicity against human NCI-N87 cells overexpressing HER2 assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human NCI-N87 cells overexpressing HER2 assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 27524310]
NCI-N87	IC₅₀	1 μM Compound: Gefitinib, Iressa	Cytotoxicity against human NCI-N87 cells expressing HER2 after 72 hrs by MTT assay Cytotoxicity against human NCI-N87 cells expressing HER2 after 72 hrs by MTT assay	[PMID: 24411123]
Non-small cell lung cancer cells	GI₅₀	7.81 μM Compound: Gefitinib	Growth inhibition of human Non-small cell lung cancer cell line incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Non-small cell lung cancer cell line incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
OVCAR-3	GI₅₀	5.01 μM Compound: Gefitinib	Growth inhibition of human OVCAR-3 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human OVCAR-3 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
OVCAR-4	GI₅₀	7.94 μM Compound: Gefitinib	Growth inhibition of human OVCAR-4 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human OVCAR-4 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
OVCAR-8	GI₅₀	10 μM Compound: Gefitinib	Growth inhibition of human OVCAR-8 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human OVCAR-8 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
PANC-1	IC₅₀	40.42 μM Compound: Gefitinib	Cytotoxicity against human PANC1 cells after 4 to 5 days by MTT assay Cytotoxicity against human PANC1 cells after 4 to 5 days by MTT assay	[PMID: 20466555]
PANC-1	IC₅₀	69.32 μM Compound: Gefitinib	Antiproliferative activity against human PANC1 cells after 48 hrs by MTT assay Antiproliferative activity against human PANC1 cells after 48 hrs by MTT assay	[PMID: 20304537]
Panel breast cells	GI₅₀	7.81 μM Compound: Gefitinib	Growth inhibition of human Panel breast (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Panel breast (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
Panel CNS (Carcinoma cell lines)	GI₅₀	8.14 μM Compound: Gefitinib	Growth inhibition of human Panel CNS (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Panel CNS (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
Panel colon cells	GI₅₀	7.02 μM Compound: Gefitinib	Growth inhibition of human Panel colon (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Panel colon (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
Panel leukemia cells	GI₅₀	3.54 μM Compound: Gefitinib	Growth inhibition of human Panel leukemia (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Panel leukemia (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
Panel melanoma cells	GI₅₀	5.28 μM Compound: Gefitinib	Growth inhibition of human Panel melanoma (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Panel melanoma (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
Panel NCI-60 cells	GI₅₀	3.24 μM Compound: Gefitinib	Anticancer activity against human Panel NCI-60 (60 carcinoma cell lines) cells assessed as cell growth inhibition incubated for 48 hrs by sulforhodamine B assay Anticancer activity against human Panel NCI-60 (60 carcinoma cell lines) cells assessed as cell growth inhibition incubated for 48 hrs by sulforhodamine B assay	[PMID: 31881454]
Panel NCI-60 cells	GI₅₀	3.24 μM Compound: Gefitinib	Growth inhibition of human Panel NCI-60 (60 carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Panel NCI-60 (60 carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
Panel ovarian cells	GI₅₀	6.63 μM Compound: Gefitinib	Growth inhibition of human Panel ovarian (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Panel ovarian (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
Panel prostate cells	GI₅₀	1.65 μM Compound: Gefitinib	Growth inhibition of human Panel prostate (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Panel prostate (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
Panel renal cells	GI₅₀	2.67 μM Compound: Gefitinib	Growth inhibition of human Panel renal (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human Panel renal (Carcinoma cell lines) incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
PC-3	GI₅₀	0.8 μM Compound: Gefitinib	Growth inhibition of human PC-3 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human PC-3 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
PC-3	IC₅₀	15.1 μM Compound: ZD-1839, IRESSA	Cytotoxicity against human PC3 cells after 96 hrs by MTT assay Cytotoxicity against human PC3 cells after 96 hrs by MTT assay	[PMID: 18313807]
PC-3	IC₅₀	2.8 μM Compound: Gefitinib	Cytotoxicity against human PC3 cells after 48 hrs by MTT assay Cytotoxicity against human PC3 cells after 48 hrs by MTT assay	10.1007/s00044-013-0734-x
PC-3	IC₅₀	22.86 μM Compound: Gefitinib	Cytotoxicity against human PC3 cells after 4 to 5 days by MTT assay Cytotoxicity against human PC3 cells after 4 to 5 days by MTT assay	[PMID: 20466555]
PC-3	IC₅₀	5.3 μM Compound: Gefitinib	Growth inhibition of human PC3 cells after 5 days by SRB assay Growth inhibition of human PC3 cells after 5 days by SRB assay	[PMID: 32484346]
PC-3	IC₅₀	7.4 μM Compound: ZD1839, Iressa	Antiproliferative activity against human PC3 cells at 10 uM after 72 hrs by MTS assay Antiproliferative activity against human PC3 cells at 10 uM after 72 hrs by MTS assay	[PMID: 21353546]
PC-3	IC₅₀	7.4 μM Compound: Iressa, Gefitinib, ZD1839	Antiproliferative activity against human PC3 cells at 10 uM by MTS assay Antiproliferative activity against human PC3 cells at 10 uM by MTS assay	10.1039/C0MD00183J
PC-3	IC₅₀	7.99 μM Compound: Gefitinib	Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30939352]
PC-3	IC₅₀	8.92 μM Compound: Gefitinib	Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 34192644]
PC-9	IC₅₀	0.0087 μM Compound: 1	Inhibition of EGFR exon 19 deletion activating mutant phosphorylation in human PC9 cells after 2 hrs by fluorescence assay Inhibition of EGFR exon 19 deletion activating mutant phosphorylation in human PC9 cells after 2 hrs by fluorescence assay	[PMID: 23930994]
PC-9	IC₅₀	0.014 μM Compound: Gefitinib	Cytotoxicity against human PC9 cells incubated for 72 hrs by MTT assay Cytotoxicity against human PC9 cells incubated for 72 hrs by MTT assay	[PMID: 23116168]
PC-9	IC₅₀	0.017 μM Compound: Gefitinib	Growth inhibition of human PC-9 cells incubated for 5 days by SRB assay Growth inhibition of human PC-9 cells incubated for 5 days by SRB assay	[PMID: 32145644]
PC-9	IC₅₀	0.063 μM Compound: Gefitinib	Antiproliferative activity against gefitinib-sensitive human PC9 cells assessed as cell viability after 72 hrs by cell titer-glo luminescence assay Antiproliferative activity against gefitinib-sensitive human PC9 cells assessed as cell viability after 72 hrs by cell titer-glo luminescence assay	[PMID: 27288180]
PC-9	IC₅₀	0.1 μM Compound: Gefitinib	Antiproliferative activity against human PC9 cells harbouring EGFR delE746-A750 mutant assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human PC9 cells harbouring EGFR delE746-A750 mutant assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31446247]
PC-9	IC₅₀	0.1 μM Compound: Gefitinib	Antiproliferative activity against human PC-9 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay Antiproliferative activity against human PC-9 cells assessed as cell growth inhibition incubated for 72 hrs by SRB assay	[PMID: 32739648]
PC-9	IC₅₀	31.32 μM Compound: Gefitinib	Antiproliferative activity against human PC9 cells harboring EGFRdel19 mutant assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human PC9 cells harboring EGFRdel19 mutant assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 32402937]
PC-9	IC₅₀	6.1 nM Compound: Gefitinib	Antiproliferative activity against human PC9 cells harboring EGFR exon-19 del mutant after 72 hrs by EZ-Cytox assay Antiproliferative activity against human PC9 cells harboring EGFR exon-19 del mutant after 72 hrs by EZ-Cytox assay	[PMID: 30554954]
PLC-PRF-5	IC₅₀	4 μM Compound: Gefitinib	Cytotoxicity against human PLC/PRF/5 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human PLC/PRF/5 cells assessed as reduction in cell viability by MTT assay	[PMID: 31013087]
RXF 393	GI₅₀	5.01 μM Compound: Gefitinib	Growth inhibition of human RXF 393 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human RXF 393 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
Sf21	IC₅₀	12 nM Compound: Gefitinib	Inhibition of human N-terminal GST-tagged EGFR kinase domain (696 to end residues) expressed in baculovirus infected sf21 cells using poly(Glu, Tyr) 4:1 as substrate Inhibition of human N-terminal GST-tagged EGFR kinase domain (696 to end residues) expressed in baculovirus infected sf21 cells using poly(Glu, Tyr) 4:1 as substrate	[PMID: 30554954]
Sf21	IC₅₀	151 nM Compound: Gefitinib	Inhibition of human C-terminal His6-tagged ERBB2 (676 to end residues) expressed in baculovirus infected sf21 cells using poly(Glu, Tyr) 4:1 as substrate Inhibition of human C-terminal His6-tagged ERBB2 (676 to end residues) expressed in baculovirus infected sf21 cells using poly(Glu, Tyr) 4:1 as substrate	[PMID: 30554954]
Sf21	IC₅₀	460 nM Compound: Gefitinib	Inhibition of human N-terminal GST-tagged EGFR T790M/L858R double mutant (696 to end residues) expressed in baculovirus infected sf21 cells using poly(Glu, Tyr) 4:1 as substrate Inhibition of human N-terminal GST-tagged EGFR T790M/L858R double mutant (696 to end residues) expressed in baculovirus infected sf21 cells using poly(Glu, Tyr) 4:1 as substrate	[PMID: 30554954]
SF-295	GI₅₀	2 μM Compound: Gefitinib	Growth inhibition of human SF-295 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SF-295 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
Sf9	IC₅₀	< 0.001 μM Compound: gefitinib	Inhibition of wild type EGFR (unknown origin) expressed in Sf9 cells pre-incubated for 30 mins before substrate and ATP addition by homogeneous time-resolved FRET assay Inhibition of wild type EGFR (unknown origin) expressed in Sf9 cells pre-incubated for 30 mins before substrate and ATP addition by homogeneous time-resolved FRET assay	[PMID: 26275028]
Sf9	IC₅₀	< 0.001 μM Compound: gefitinib	Inhibition of EGFR L858R mutant (unknown origin) expressed in Sf9 cells pre-incubated for 60 mins before substrate and ATP addition by homogeneous time-resolved FRET assay Inhibition of EGFR L858R mutant (unknown origin) expressed in Sf9 cells pre-incubated for 60 mins before substrate and ATP addition by homogeneous time-resolved FRET assay	[PMID: 26275028]
Sf9	IC₅₀	> 1 μM Compound: 1	Irreversible inhibition of human recombinant GST-tagged JAK3 expressed in baculovirus infected Sf9 insect cells assessed as reduction in polyglutamic acid-tyrosine phosphorylation after 30 mins by ELISA Irreversible inhibition of human recombinant GST-tagged JAK3 expressed in baculovirus infected Sf9 insect cells assessed as reduction in polyglutamic acid-tyrosine phosphorylation after 30 mins by ELISA	[PMID: 27491023]
Sf9	IC₅₀	0.003 μM Compound: 1	Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA Irreversible inhibition of GST-tagged ERBB1 (unknown origin) (Met-668 to Ala-1211 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA	[PMID: 27491023]
Sf9	IC₅₀	0.02 μM Compound: Gefitinib, Iressa	Inhibition of recombinant His6-tagged EGFR expressed in baculovirus infected insect Sf9 cells using ATP as substrate and cofactor MgCl2 after 2 hrs by DELFIA/Time-resolved fluorometric analysis Inhibition of recombinant His6-tagged EGFR expressed in baculovirus infected insect Sf9 cells using ATP as substrate and cofactor MgCl2 after 2 hrs by DELFIA/Time-resolved fluorometric analysis	[PMID: 22119130]
Sf9	IC₅₀	0.033 μM Compound: Iressa	Inhibition of EGFR expressed in Sf9 cells assessed as inhibition of receptor autophosphorylation by DELFIA time resolved fluorimetry Inhibition of EGFR expressed in Sf9 cells assessed as inhibition of receptor autophosphorylation by DELFIA time resolved fluorimetry	[PMID: 20056425]
Sf9	IC₅₀	0.1 μM Compound: gefitinib	Inhibition of EGFR L858R/T790M mutant (unknown origin) expressed in Sf9 cells pre-incubated for 60 mins before substrate and ATP addition by homogeneous time-resolved FRET assay Inhibition of EGFR L858R/T790M mutant (unknown origin) expressed in Sf9 cells pre-incubated for 60 mins before substrate and ATP addition by homogeneous time-resolved FRET assay	[PMID: 26275028]
Sf9	IC₅₀	0.343 μM Compound: 1	Irreversible inhibition of GST-tagged ERBB2 (unknown origin) (Ile-675 to Val-1256 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA Irreversible inhibition of GST-tagged ERBB2 (unknown origin) (Ile-675 to Val-1256 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA	[PMID: 27491023]
Sf9	IC₅₀	0.39 μM Compound: Gefitinib	Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo kinase assay Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo kinase assay	[PMID: 31718182]
Sf9	IC₅₀	0.476 μM Compound: 1	Irreversible inhibition of GST-tagged ERBB4 (unknown origin) (Gly-259 to Gly-690 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA Irreversible inhibition of GST-tagged ERBB4 (unknown origin) (Gly-259 to Gly-690 residues) expressed in baculovirus infected Sf9 insect cells assessed as reduction in Glu/Tyr copolymer phosphorylation after 6 mins by ELISA	[PMID: 27491023]
Sf9	IC₅₀	15 nM Compound: Gefitinib	Inhibition of human GST-tagged EGFR L834R mutant expressed in Sf9 cells by luminescence assay Inhibition of human GST-tagged EGFR L834R mutant expressed in Sf9 cells by luminescence assay	[PMID: 23611691]
Sf9	IC₅₀	15.5 nM Compound: Gefitinib	Inhibition of wild-type human N-terminal GST-tagged EGFR (695 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate after 60 mins in presence of ATP by ADP-Glo assay Inhibition of wild-type human N-terminal GST-tagged EGFR (695 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate after 60 mins in presence of ATP by ADP-Glo assay	[PMID: 30471829]
Sf9	IC₅₀	3.17 μM Compound: Gefitinib	Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR L858R/T790M/C797S mutant (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo ki Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR L858R/T790M/C797S mutant (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo ki	[PMID: 31718182]
Sf9	IC₅₀	33 nM Compound: Gefitinib	Inhibition of human wild type GST-tagged EGFR kinase domain expressed in Sf9 cells by luminescence assay Inhibition of human wild type GST-tagged EGFR kinase domain expressed in Sf9 cells by luminescence assay	[PMID: 23611691]
Sf9	IC₅₀	4.99 μM Compound: Gefitinib	Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR L858R/T790M double mutant (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo k Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR L858R/T790M double mutant (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo k	[PMID: 31718182]
Sf9	IC₅₀	823.3 nM Compound: Gefitinib	Inhibition of human N-terminal GST-tagged EGFR T790M/L858R double mutant (695 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate after 60 mins in presence of ATP by ADP-Glo assay Inhibition of human N-terminal GST-tagged EGFR T790M/L858R double mutant (695 to end residues) expressed in baculovirus infected Sf9 insect cells using Poly (4:1 Glu, Tyr) as substrate after 60 mins in presence of ATP by ADP-Glo assay	[PMID: 30471829]
SGC-7901	IC₅₀	10.26 μM Compound: Iressa	Cytotoxicity against human SGC7901 cells after 72 hrs by MTT assay Cytotoxicity against human SGC7901 cells after 72 hrs by MTT assay	[PMID: 22727449]
SGC-7901	IC₅₀	29.01 μM Compound: Gefitinib	Cytotoxicity against human SGC-7901 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human SGC-7901 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32866757]
SH-SY5Y	IC₅₀	18.21 μM Compound: Gefitinib	Antiproliferative activity against human SH-SY5Y cells after 72 hrs by MTT assay Antiproliferative activity against human SH-SY5Y cells after 72 hrs by MTT assay	[PMID: 28711702]
SH-SY5Y	IC₅₀	18.21 μM Compound: 2	Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay	[PMID: 23871909]
SH-SY5Y	IC₅₀	18.216 μM Compound: Gefitinib	Antiproliferative activity against human SH-SY5Y cells incubated for 72 hrs by MTT assay Antiproliferative activity against human SH-SY5Y cells incubated for 72 hrs by MTT assay	[PMID: 31488358]
SK-BR-3	IC₅₀	2518 nM Compound: Gefitinib	Antiproliferative activity against HER2-dependant human SKBR3 cells after 72 hrs by EZ-Cytox assay Antiproliferative activity against HER2-dependant human SKBR3 cells after 72 hrs by EZ-Cytox assay	[PMID: 30554954]
SK-BR-3	IC₅₀	4.92 μM Compound: Gefitinib	Antiproliferative activity against human SK-BR-3 cells after 72 hrs by MTT assay Antiproliferative activity against human SK-BR-3 cells after 72 hrs by MTT assay	[PMID: 27132165]
SK-BR-3	IC₅₀	5.36 μM Compound: Gefitinib	Cytotoxicity against human SKBR3 cells expressing wild type EGFR assessed as growth inhibition incubated for 1 hr prior to EGF challenge measured after 72 hrs by luciferase reporter gene assay Cytotoxicity against human SKBR3 cells expressing wild type EGFR assessed as growth inhibition incubated for 1 hr prior to EGF challenge measured after 72 hrs by luciferase reporter gene assay	10.1039/C3MD00118K
SK-HEP1	IC₅₀	10.1 μM Compound: Gefitinib	Cytotoxicity against human SKHEP1 cells after 72 hrs by SRB assay Cytotoxicity against human SKHEP1 cells after 72 hrs by SRB assay	[PMID: 29407971]
SK-MEL-28	IC₅₀	> 20 μM Compound: 3	Antiproliferative activity against human SK-MEL-28 cells harboring BRAF V600E mutant after 68 hrs by MTS assay Antiproliferative activity against human SK-MEL-28 cells harboring BRAF V600E mutant after 68 hrs by MTS assay	[PMID: 24588073]
SK-MEL-28	GI₅₀	0.32 μM Compound: Gefitinib	Growth inhibition of human SK-MEL-28 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SK-MEL-28 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
SK-OV-3	IC₅₀	24.5 μM Compound: Gefitinib	Antiproliferative activity against human SK-OV-3 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Antiproliferative activity against human SK-OV-3 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 32739648]
SMMC-7721	IC₅₀	33.12 μM Compound: Gefitinib	Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay	[PMID: 20304537]
SMMC-7721	IC₅₀	4.16 μM Compound: Gefitinib	Antiproliferative activity against human SMMC7721 cells over expressing EGFR after 48 hrs by MTT assay Antiproliferative activity against human SMMC7721 cells over expressing EGFR after 48 hrs by MTT assay	[PMID: 27118497]
SMMC-7721	IC₅₀	9.2 μM Compound: Gefitinib	Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability by MTT assay	[PMID: 31013087]
SNB-75	GI₅₀	6.31 μM Compound: Gefitinib	Growth inhibition of human SNB-75 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SNB-75 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
SNU-638	IC₅₀	7.56 μM Compound: Gefitinib	Cytotoxicity against human SNU638 cells after 72 hrs by SRB assay Cytotoxicity against human SNU638 cells after 72 hrs by SRB assay	[PMID: 29407971]
SR	GI₅₀	3.16 μM Compound: Gefitinib	Growth inhibition of human SR cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human SR cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
SW480	IC₅₀	12.5 μM Compound: ZD1839	Antiproliferative activity against human SW480 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human SW480 cells incubated for 72 hrs by MTT assay	[PMID: 31202990]
SW480	IC₅₀	12.5 μM Compound: Gefitinib	Antiproliferative activity against human SW480 cells harboring wild type EGFR after 72 hrs by MTT assay Antiproliferative activity against human SW480 cells harboring wild type EGFR after 72 hrs by MTT assay	[PMID: 29421573]
SW480	IC₅₀	12.5 μM Compound: Gefitinib	Antiproliferative activity against human SW480 cells harboring wild type EGFR after 72 hrs by MTT assay Antiproliferative activity against human SW480 cells harboring wild type EGFR after 72 hrs by MTT assay	[PMID: 28711703]
SW-620	IC₅₀	> 10 μM Compound: 1	Cytotoxicity against human SW620 cells after 72 hrs by MTT assay Cytotoxicity against human SW620 cells after 72 hrs by MTT assay	[PMID: 20151670]
SW-620	IC₅₀	28.2 μM Compound: Gefitinib	Cytotoxicity against human SW620 cells after 48 hrs by CellTiter-Glo assay Cytotoxicity against human SW620 cells after 48 hrs by CellTiter-Glo assay	[PMID: 24900594]
T-24	IC₅₀	14.6 μM Compound: Gef	Antiproliferative activity against human T-24 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay Antiproliferative activity against human T-24 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay	[PMID: 32827851]
TK-10	GI₅₀	0.1 μM Compound: Gefitinib	Growth inhibition of human TK-10 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human TK-10 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
U-251	GI₅₀	10 μM Compound: Gefitinib	Growth inhibition of human U-251 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human U-251 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
U-87MG ATCC	IC₅₀	22.4 μM Compound: 1	Antiproliferative activity against human U-87MG cells harboring wild type EGFR assessed as inhibition of cell growth by MTT assay Antiproliferative activity against human U-87MG cells harboring wild type EGFR assessed as inhibition of cell growth by MTT assay	[PMID: 31869655]
U-87MG ATCC	IC₅₀	8.2 μM Compound: Gefitinib	Antiproliferative activity against human U87 cells after 48 hrs by MTT assay Antiproliferative activity against human U87 cells after 48 hrs by MTT assay	[PMID: 28462838]
UACC-257	GI₅₀	6.31 μM Compound: Gefitinib	Growth inhibition of human UACC-257 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human UACC-257 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
UACC-62	GI₅₀	5.01 μM Compound: Gefitinib	Growth inhibition of human UACC-62 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human UACC-62 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
UO-31	GI₅₀	1.26 μM Compound: Gefitinib	Growth inhibition of human UO-31 cells incubated for 48 hrs by sulforhodamine B assay Growth inhibition of human UO-31 cells incubated for 48 hrs by sulforhodamine B assay	[PMID: 27241691]
Vero	IC₅₀	> 10 μM Compound: 1	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 30655941]
Vero	IC₅₀	> 100 μM Compound: Gefitinib	Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay	[PMID: 28927795]
WM 266-4	IC₅₀	17.42 μM Compound: Gefitinib	Antiproliferative activity against human WM266.4 cells assessed as inhibition of cell viability after 48 hrs by MTS assay Antiproliferative activity against human WM266.4 cells assessed as inhibition of cell viability after 48 hrs by MTS assay	[PMID: 31494469]

体外研究
(In Vitro)

Gefitinib (0.01-0.1 μM, 72 h) results in increased phosphotyrosine load of the receptor, increased signalling to ERK and stimulation of proliferation and anchorage-independent growth^[2].
Gefitinib (1-2 μM, 72 h) significantly decreases EGFRvIII phosphotyrosine load, EGFRvIII-mediated proliferation and anchorage-independent growth^[2].
Gefitinib (0.62 μM, 24-72 h) inhibits IL-13-induced M2-like polarization of RAW 264.7 cells through the STAT6-dependent signaling pathway^[3].
Gefitinib (0.62 μM, 72 h) inhibits M2-like macrophage-promoted invasion and migration^[3].
Gefitinib (0-10 μM, 72 h) induces apoptosis (induction of BIM protein) in NSCLC Cell Lines (H3255 and HCC827 cells)^[4].
Gefitinib (100 nM, 24 h) suppresses macropinocytosis and increases the cellular uptake of extracellular vesicles( EVs) in HCC827 and A549 cells^[6].
Gefitinib (1.5-60 μM, 48 h) increases inhibition of proliferation in H358^R and A549^R cells (Cisplatin-resistant wtEGFR NSCLC cell lines)^[7].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[2]

Cell Line:	NR6wtEGFR, NR6W and NR6M
Concentration:	1, 10, 100 μM
Incubation Time:	5 h
Result:	Inhibited EGFR tyrosine phosphorylations.

Cell Migration Assay ^[3]

Cell Line:	LLCs cell
Concentration:	0.62 μM
Incubation Time:	72 h
Result:	Abrogated M2-like macrophage promoted invasion and migration of LLCs.

体内研究
(In Vivo)

Gefitinib (Oral administration, 75 mg/kg/d, 21 days) inhibits the M2-like polarization of macrophages in LLC mice metastasis model^[3].
Gefitinib (Oral administration, 75 mg/kg for the initial week, daily for 5 consecutive days per week) eliminates phosphorylation of HER2 and HER3 and signaling through MAPK and Akt in lobular hyperplasias and carcinomas, increases MAPK activity and cytokine production in splenocytes and lymph nodes^[5]. Gefitinib (Oral gavage, 150 mg/kg, daily) enhances the anti-tumor effect of Cisplatin in H358^R xenograft^[7].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	LLC mice metastasis model^[3]
Dosage:	75 mg/kg/d, for 21 days.
Administration:	Oral administration
Result:	Reduced the number of lung metastasis nodules, down-regulated the expression of M2 marker genes and the percentages CD206⁺ and CD68⁺ macrophages in tumor tissues.

Animal Model:	BALB-NeuT transgenic mouse model^[5]
Dosage:	75 mg/kg for the initial week, and increased by 15 mg/kg every other week, daily for 5 consecutive days per week, followed by 2 days without treatment and repeated for 8–9 weeks.
Administration:	Oral administration
Result:	Reduced tumor multiplicity from 9.6 to 0.58 (83%), and reduced the number and size of lobules and lobular nodules in treated mice.

Clinical Trial

分子量

446.90

Formula

C₂₂H₂₄ClFN₄O₃

CAS 号

184475-35-2

性状

固体

颜色

White to off-white

中文名称

吉非替尼；吉菲替尼

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

溶解性数据

细胞实验：

DMSO 中的溶解度 : 100 mg/mL (223.76 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.2376 mL	11.1882 mL	22.3764 mL
5 mM	0.4475 mL	2.2376 mL	4.4753 mL
10 mM	0.2238 mL	1.1188 mL	2.2376 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C储存时，请在2年内使用， -20°C储存时，请在1年内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (5.59 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。
方案二

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.65 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案三

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.65 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案四

请依序添加每种溶剂： 1% DMSO 99% Saline
Solubility: 0.5 mg/mL (1.12 mM); 悬浊液; 超声助溶

以下溶解方案，请直接配制工作液。建议现用现配，在短期内尽快用完。以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。

方案一

请依序添加每种溶剂： Corn Oil
Solubility: 5 mg/mL (11.19 mM); 悬浊液; 超声助溶

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.94%

选择批次：

Data Sheet (638 KB) SDS (393 KB)

COA (288 KB) LCMS (102 KB) 元素分析报告 (211 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Wakeling AE, et al. ZD1839: an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 2002 Oct 15;62(20):5749-54. [Content Brief]

[2]. Pedersen MW, et al. Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII. Br J Cancer. 2005 Oct 17;93(8):915-23. [Content Brief]

[3]. Muhammad Tariq, et al. Gefitinib inhibits M2-like polarization of tumor-associated macrophages in Lewis lung cancer by targeting the STAT6 signaling pathway. Acta Pharmacol Sin. 2017 Nov;38(11):1501-1511. [Content Brief]

[4]. Mark S Cragg, et al. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med. 2007 Oct;4(10):1681-89; discussion 1690. [Content Brief]

[5]. Marie P Piechocki, et al. Gefitinib prevents cancer progression in mice expressing the activated rat HER2/neu. Int J Cancer. 2008 Apr 15;122(8):1722-9. [Content Brief]

[6]. Tomoya Takenaka, et al. Effects of gefitinib treatment on cellular uptake of extracellular vesicles in EGFR-mutant non-small cell lung cancer cells. Int J Pharm. 2019 Dec 15;572:118762. [Content Brief]

[7]. Amin Li, et al. Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells. J Cancer Res Clin Oncol. 2020 Jul;146(7):1737-1749. [Content Brief]

Gefitinib 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.2376 mL	11.1882 mL	22.3764 mL	55.9409 mL
	5 mM	0.4475 mL	2.2376 mL	4.4753 mL	11.1882 mL
	10 mM	0.2238 mL	1.1188 mL	2.2376 mL	5.5941 mL
	15 mM	0.1492 mL	0.7459 mL	1.4918 mL	3.7294 mL
	20 mM	0.1119 mL	0.5594 mL	1.1188 mL	2.7970 mL
	25 mM	0.0895 mL	0.4475 mL	0.8951 mL	2.2376 mL
	30 mM	0.0746 mL	0.3729 mL	0.7459 mL	1.8647 mL
	40 mM	0.0559 mL	0.2797 mL	0.5594 mL	1.3985 mL
	50 mM	0.0448 mL	0.2238 mL	0.4475 mL	1.1188 mL
	60 mM	0.0373 mL	0.1865 mL	0.3729 mL	0.9323 mL
	80 mM	0.0280 mL	0.1399 mL	0.2797 mL	0.6993 mL
	100 mM	0.0224 mL	0.1119 mL	0.2238 mL	0.5594 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.

Gefitinib (Synonyms: 吉非替尼; ZD1839)

Customer Review

Other Forms of Gefitinib:

MCE 顾客使用本产品发表的 133 篇科研文献

Gefitinib 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 EGFR 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Gefitinib 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Gefitinib (Synonyms: 吉非替尼; ZD1839)

Customer Review

Other Forms of Gefitinib:

Gefitinib 相关抗体

MCE 顾客使用本产品发表的 133 篇科研文献

Gefitinib 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 EGFR 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

Gefitinib 相关抗体:

摩尔计算器

稀释计算器

Gefitinib 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z